<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">66107</article-id><article-id pub-id-type="doi">10.7554/eLife.66107</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Modeling the <italic>ACVR1</italic><sup><italic>R206H</italic></sup> mutation in human skeletal muscle stem cells</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-157649"><name><surname>Barruet</surname><given-names>Emilie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4593-024X</contrib-id><email>emilie.barruet@ucsf.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157648"><name><surname>Garcia</surname><given-names>Steven M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7833-6677</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157650"><name><surname>Wu</surname><given-names>Jake</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/></contrib><contrib contrib-type="author" id="author-181728"><name><surname>Morales</surname><given-names>Blanca M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157654"><name><surname>Tamaki</surname><given-names>Stanley</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222118"><name><surname>Moody</surname><given-names>Tania</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-31341"><name><surname>Pomerantz</surname><given-names>Jason H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5107-1883</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-89188"><name><surname>Hsiao</surname><given-names>Edward C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8924-106X</contrib-id><email>Edward.Hsiao@ucsf.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Division of Plastic and Reconstructive Surgery, Departments of Surgery and Orofacial Sciences, the Program in Craniofacial Biology, and the Eli and Edythe Broad Center of Regeneration Medicine, University of California - San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Division of Endocrinology and Metabolism, Department of Medicine, the Institute for Human Genetics, the Program in Craniofacial Biology, and the Eli and Edythe Broad Center of Regeneration Medicine, University of California - San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Division of Plastic and Reconstructive Surgery, Department of Surgery, University of California - San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ackert-Bicknell</surname><given-names>Cheryl</given-names></name><role>Reviewing Editor</role><aff><institution>University of Colorado</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cheah</surname><given-names>Kathryn Song Eng</given-names></name><role>Senior Editor</role><aff><institution>The University of Hong Kong</institution><country>Hong Kong</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>10</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e66107</elocation-id><history><date date-type="received" iso-8601-date="2020-12-29"><day>29</day><month>12</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-11-09"><day>09</day><month>11</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Barruet et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Barruet et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-66107-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-66107-figures-v2.pdf"/><abstract><p>Abnormalities in skeletal muscle repair can lead to poor function and complications such as scarring or heterotopic ossification (HO). Here, we use fibrodysplasia ossificans progressiva (FOP), a disease of progressive HO caused by <italic>ACVR1</italic><sup><italic>R206H</italic></sup> (Activin receptor type-1 receptor) mutation, to elucidate how ACVR1 affects skeletal muscle repair. Rare and unique primary FOP human muscle stem cells (Hu-MuSCs) isolated from cadaveric skeletal muscle demonstrated increased extracellular matric (ECM) marker expression, showed skeletal muscle-specific impaired engraftment and regeneration ability. Human induced pluripotent stem cell (iPSC)-derived muscle stem/progenitor cells (iMPCs) single-cell transcriptome analyses from FOP also revealed unusually increased ECM and osteogenic marker expression compared to control iMPCs. These results show that iMPCs can recapitulate many aspects of Hu-MuSCs for detailed in vitro study; that ACVR1 is a key regulator of Hu-MuSC function and skeletal muscle repair; and that ACVR1 activation in iMPCs or Hu-MuSCs may contribute to HO by changing the local tissue environment.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>human satellite cells hu-SCs</kwd><kwd>human muscle stem cells hu-MuSCs</kwd><kwd>human induced pluripotent stem cells iPSCs</kwd><kwd>ACVR1</kwd><kwd>heterotopic ossification</kwd><kwd>fibrodysplasia ossificans progressivav FOP</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>R01AR066735</award-id><principal-award-recipient><name><surname>Hsiao</surname><given-names>Edward C</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100013465</institution-id><institution>French Muscular Dystrophy Association</institution></institution-wrap></funding-source><award-id>Trampoline grant</award-id><principal-award-recipient><name><surname>Barruet</surname><given-names>Emilie</given-names></name><name><surname>Hsiao</surname><given-names>Edward C</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Radiant Hope Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hsiao</surname><given-names>Edward C</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008069</institution-id><institution>University of California, San Francisco</institution></institution-wrap></funding-source><award-id>UCSF Cohort Development Grant</award-id><principal-award-recipient><name><surname>Hsiao</surname><given-names>Edward C</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000900</institution-id><institution>California Institute for Regenerative Medicine</institution></institution-wrap></funding-source><award-id>TG2-01153</award-id><principal-award-recipient><name><surname>Barruet</surname><given-names>Emilie</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008069</institution-id><institution>University of California, San Francisco</institution></institution-wrap></funding-source><award-id>UCSF Program for Breakthrough Biomedical Research</award-id><principal-award-recipient><name><surname>Barruet</surname><given-names>Emilie</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>R01AR072638-03</award-id><principal-award-recipient><name><surname>Pomerantz</surname><given-names>Jason H</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Novel human iPS cell derived and primary skeletal muscle stem cells show that abnormal ACVR1 activation increases osteogenic/ECM gene expression and impairs myofiber repair, while revealing muscle-specific regenerative properties.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Human diseases of skeletal muscle are major medical problems. Aberrant repair after muscle injury can results in scarring, fibrosis, lipid infiltration, or heterotopic ossification (HO; bone formation in an inappropriate site). Although HO is a relatively uncommon complication, it can form after trauma, burns, spinal cord injuries, and surgical procedures such as hip arthroplasty (<xref ref-type="bibr" rid="bib1">Agarwal et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Matsuo et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Meyers et al., 2019</xref>; <xref ref-type="bibr" rid="bib64">Sullivan et al., 2013</xref>). Recently, HO has been reported in patients with severe COVID-19, suggesting a critical role for inflammation and muscle damage (<xref ref-type="bibr" rid="bib4">Aziz et al., 2021</xref>).</p><p>To better understand the link between skeletal muscle and HO, we studied fibrodysplasia ossificans progressiva (FOP) as a prototypical condition. FOP is a congenital disease of abnormal skeletal muscle regeneration and severe HO, in which the majority of patients have the classical <italic>ACVR1</italic><sup><italic>R206H</italic></sup> (c.617&gt; A) mutation (<xref ref-type="bibr" rid="bib57">Shore Eileen et al., 2006</xref>) that causes hyperactivation of the BMP-SMAD signaling (<xref ref-type="bibr" rid="bib11">Billings et al., 2008</xref>) and aberrant responses to Activin A (<xref ref-type="bibr" rid="bib29">Hatsell et al., 2015</xref>). While previous studies suggested that multiple cell types including endothelial cells (<xref ref-type="bibr" rid="bib5">Barruet et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Medici et al., 2010</xref>), mesenchymal progenitors (<xref ref-type="bibr" rid="bib20">Culbert et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Dey et al., 2016</xref>), pericytes (<xref ref-type="bibr" rid="bib14">Cai et al., 2015</xref>), and more recently mast cells (<xref ref-type="bibr" rid="bib13">Brennan et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Convente et al., 2018</xref>), macrophages (<xref ref-type="bibr" rid="bib6">Barruet et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Matsuo et al., 2021</xref>), and FAPs (<xref ref-type="bibr" rid="bib35">Lees-Shepard et al., 2018</xref>) can indirectly or directly contribute to HO in FOP, how the <italic>ACVR1</italic><sup><italic>R206H</italic></sup> mutation impairs human muscle repair and muscle stem cell function has yet to be determined.</p><p>Disrupted signaling of bone morphogenetic proteins (BMPs), originally identified by their ability to induce bone formation when injected into muscle (<xref ref-type="bibr" rid="bib68">Urist, 1965</xref>), changes muscle homeostasis (<xref ref-type="bibr" rid="bib47">Ono et al., 2011</xref>) by controlling the proliferation and differentiation of satellite cells (SCs) (<xref ref-type="bibr" rid="bib47">Ono et al., 2011</xref>; <xref ref-type="bibr" rid="bib62">Stantzou et al., 2017</xref>). SCs marked by PAX7 (Paired Box 7) (<xref ref-type="bibr" rid="bib51">Seale et al., 2000</xref>), are a prerequisite for skeletal muscle regeneration (<xref ref-type="bibr" rid="bib41">Mauro, 1961</xref>) and are thought to be the main human muscle stem cells (Hu-MuSCs) of postnatal skeletal muscle. Upon injury, activated SCs give rise to myoblasts, which form new myofibers or fuse to existing muscle fibers to repair muscle damage (<xref ref-type="bibr" rid="bib34">Kuang et al., 2007</xref>). A subset of SCs does not differentiate and serves to replenish the SC pool. The BMP pathway is critical for maintaining <italic>PAX7</italic> expression in primary MuSCs and for preventing commitment to myogenic differentiation (<xref ref-type="bibr" rid="bib24">Friedrichs et al., 2011</xref>). Abrogation of BMP signaling in SCs slowed myofiber growth (<xref ref-type="bibr" rid="bib62">Stantzou et al., 2017</xref>), and increased BMP4 levels in Duchenne’s muscular dystrophy (DMD) can exacerbate the disease (<xref ref-type="bibr" rid="bib55">Shi et al., 2013</xref>). However, how the BMP pathway regulates muscle repair or SC function in conditions of HO such as FOP remains unclear and is a major knowledge gap.</p><p>Since primary tissues can only and safely be obtained from deceased FOP patients because of the risks of heterotopic ossification at the surgical site, patient-derived human-induced pluripotent stem cells (hiPSCs) provide a strategy to create FOP cells for in vitro and mouse xeno-transplant studies. Interestingly, BMP signaling is a key pathway that can be manipulated to make Hu-MuSCs-like cells from hiPSCs (iMPCs) (<xref ref-type="bibr" rid="bib15">Chal et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">Chal et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Xi et al., 2017</xref>). Recent protocols to create Hu-MuSCs-like cells from hiPSCs (<xref ref-type="bibr" rid="bib65">Takahashi et al., 2007</xref>) could generate skeletal myogenic lineage cells, but with limited muscle regenerative capacity (<xref ref-type="bibr" rid="bib12">Borchin et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Magli et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Shelton et al., 2014</xref>; <xref ref-type="bibr" rid="bib69">van der Wal et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Xi et al., 2017</xref>). PAX7 cell engraftment capability was often not reported or showed limited success. Transgene-induced <italic>PAX7</italic> or <italic>PAX3</italic> expression in hiPSCs can increase engraftment of PAX7<sup>+</sup> cells and contribution to the SC pool (<xref ref-type="bibr" rid="bib2">Al Tanoury et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Wu et al., 2018</xref>); however, these engineered cells may not reflect physiology due to the genetic manipulation of these master transcription factors.</p><p>In this study, we used primary human muscle stem cells isolated from deceased FOP subjects and hiPSC-derived muscle progenitor cells from FOP subjects to elucidate how <italic>ACVR1</italic><sup><italic>R206H</italic></sup> affects muscle stem cell function and regenerative ability. Primary FOP Hu-MuSCs can engraft and regenerate injured muscle of immunocompromised (NSG) mice, but at lower efficiency than Hu-MuSCs from non-FOP donors, and the source of FOP Hu-MuSCs (biceps vs. diaphragm) appears to impact their engraftment efficiency. A new non-transgenic strategy for creating human iMPCs was developed and applied to multiple hiPSC lines from control subjects and subjects with FOP. These iMPCs shared transcriptional similarities with primary Hu-MuSCs, and abnormal activation of the BMP pathway by <italic>ACVR1</italic><sup><italic>R206H</italic></sup> changed the transcription profiles of the FOP iMPCs compared to controls.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Lower efficiency engraftment of primary human FOP Hu-MuSCs</title><p>Muscle tissue samples were obtained from FOP cadavers which allowed the study of markers in situ and the isolation of primary human cells with endogenous activated ACVR1 signaling. Hematoxylin and eosin and alcian blue staining of FOP primary muscle samples from two deceased FOP subjects in a region without HO showed no gross defects. FOP muscle tissue near a HO lesion showed increased ECM proteoglycan components (alcian blue staining) in the interstitial space of the muscle fibers near the HO lesion (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Primary Hu-MuSCs carrying the <italic>ACVR1</italic><sup><italic>R206H</italic></sup> activating mutation were isolated from unfixed muscle tissue from two FOP autopsies. Biceps brachii muscle, commonly affected by HO, and diaphragm muscle, one of the rare skeletal muscle sites spared from HO in patients with FOP, were analyzed. PAX7 staining confirmed the presence of SCs in human FOP biceps (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, middle and right). Interestingly, a small subregion showed Collagen Type 1 expression with embedded satellite cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, right) suggesting possible early HO formation despite absence of gross HO.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Regenerative properties of primary Hu-MuSCs isolated from FOP patients.</title><p>(<bold>A</bold>) Hematoxylin and eosin staining (top) and alcian blue staining (bottom) of muscle cross sections from FOP subjects, with no heterotopic ossification (left) and with heterotopic ossification, depicted by the white dashed line (right, 100 µm scale bar). (<bold>B</bold>) Immunofluorescence staining for PAX7 and COL1 of muscle cross sections from control and FOP subjects. White arrowheads mark Hu-MuSCs, 50 µm scale bar. (<bold>C</bold>) Heat map of normalized gene expression of sorted human satellite cells from two control subjects and two different muscles of 1 FOP subject. (<bold>D</bold>) Schematic and experimental time course. Hu-MuSCs from biceps and diaphragm muscles of a deceased FOP patient were sorted and transplanted into NSG mice. (<bold>E</bold>) Immunofluorescence staining 5 weeks after xenotransplantation. White arrowheads mark Hu-MuSCs, 50 µm scale bar. (<bold>F</bold>) Quantification of human DYSTROPHIN fibers and human PAX7<sup>+</sup> cells 5 weeks after transplant. (<bold>G</bold>) Mice were re-injured 5 weeks after transplantation with bupivacaine. Immunofluorescence staining was performed at week 10. White arrows mark Hu-MuSCs, 50 µm scale bar. (<bold>H</bold>) Quantification of human DYSTROPHIN fibers and human PAX7<sup>+</sup> cells after re-injury at week 10. n = 1, biological replicates, n ≥ 3 technical replicates. Error bars represent mean and SD. *, p &lt; 0.05, **, p &lt; 0.01. Muscle specimen and transplantation details are listed in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref> .</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Muscle specimen information.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-66107-fig1-data1-v2.docx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Hu-MuSCs transplantation details.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-66107-fig1-data2-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Transplanted Hu-MuSCs from biceps and diaphragm of FOP patient do not form bone.</title><p>(<bold>A</bold>) Flow cytometry analysis sorting strategy to isolate human satellite cells. (<bold>B</bold>) Representative immunostaining of Hu-MuSCs. White arrows indicate PAX7+ satellite cells (scale bar, 50 µm). (<bold>C</bold>) X-ray of transplanted mice at 5 and 10 weeks after initial transplantation (scale bars, 4 mm (week 5), 7 mm (week 10)) showing no heterotopic ossification. Details about muscle specimens used in this figure are in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Sufficient Hu-MuSCs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) were sorted for transplant and gene expression analysis. FOP Hu-MuSCs showed lower <italic>PAX7</italic> expression compared to control Hu-MuSCs. <italic>COL1A1</italic> and <italic>ID3</italic> were increased in affected FOP muscle (biceps) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). However, <italic>ID1</italic> was increased in both the FOP diaphragm and biceps compared to control muscles (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Hu-MuSCs were transplanted into the irradiated tibialis anterior (TA) muscle of immunocompromised (NSG) mice (to hinder endogenous satellite cells) previously injured with bupivacaine (<xref ref-type="bibr" rid="bib26">Garcia et al., 2017</xref>). The bupivicaine step induces myofiber injury and promotes engraftment of donor Hu-MuSCs. Five weeks after transplantation, biceps and diaphragm FOP Hu-MuSCs had engrafted and formed human fibers (<xref ref-type="fig" rid="fig1">Figure 1D and E</xref>). However, the number of human DYSTROPHIN-positive fibers was significantly lower with FOP Hu-MuSCs vs. control Hu-MuSCs (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). The number of engrafted PAX7<sup>+</sup> cells was qualitatively lower with FOP vs. control Hu-MuSCs (<xref ref-type="fig" rid="fig1">Figure 1F</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Ten weeks after re-injury with bupivacaine at week 5 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), the number of human DYSTROPHIN fibers was significantly decreased when FOP biceps Hu-MuSCs were transplanted compared to control Hu-MuSCs, but not when FOP diaphragm Hu-MuSCs were transplanted (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>). No differences in the number of human PAX7 cells were identified (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>). No radiologic evidence of HO was found in any mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).</p><p>Thus, primary Hu-MuSCs isolated from two FOP subjects can engraft and regenerate injured muscle of NSG mice. Our limited sample size suggests this may occur at lower efficiency than control MuSCs. In addition, the results suggest that the source of FOP Hu-MuSCs (biceps or diaphragm) may impact MuSC engraftment efficiency.</p></sec><sec id="s2-2"><title>Human FOP iPSCs can differentiate into skeletal muscle cells</title><p>The rarity of FOP disease and difficulty obtaining human tissue samples from patients with FOP makes it difficult to obtain a reliable source of muscle stem cells. Therefore, we used established and fully characterized control hiPSCs (Wtc11, 1323–2, and BJ2) and <italic>ACVR1</italic><sup><italic>R206H</italic></sup> hiPSCs (F1-1, F2-3, F3-2) lines previously derived from patients with FOP (<xref ref-type="bibr" rid="bib38">Matsumoto et al., 2013</xref>). We first asked whether our lines were able to differentiate into myogenic cells and specifically into muscle stem cell-like cells using an adapted version of recently published protocols (<xref ref-type="bibr" rid="bib31">Hicks et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Shelton et al., 2014</xref>; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). The control hiPSCs yielded PAX7, MYOGENIN-expressing cells (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), expressed DYSTROPHIN (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), and formed contractile myotubes (<xref ref-type="fig" rid="fig2">Figure 2C</xref>; <xref ref-type="video" rid="video1">Video 1</xref> and <xref ref-type="video" rid="video2">Video 2</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Skeletal muscle differentiation of human control and FOP hiPSC lines.</title><p>(<bold>A</bold>) Differentiation schematic of hiPSCs into skeletal muscle stem cell-like cells (iMPCs). (<bold>B</bold>) Immunofluorescence staining for PAX7, DYSTROPHIN and nuclear stain DAPI of iMPCs at day 50, 50 µm scale bar. (<bold>C</bold>) Immunofluorescence staining of PAX7 and MYOGENIN expressing cells. Control and FOP hiPSCs can form contractile myotubes, 100 µm scale bar. (<bold>D</bold>) <italic>PAX7</italic>, <italic>MYF5</italic>, <italic>MYOD1,</italic> and <italic>MYOGENIN</italic> gene expression at day 50 of differentiation (n = 3 biological replicates and n ≥ 3 technical replicates). Error bars represent mean ± SD. No statistically significant differences were detected. (<bold>E</bold>) Schematic describing the addition of the BMP pathway inhibitor LDN193189 (LDN). (<bold>F</bold>) Representative immunofluorescence staining of 2 control and 2 FOP hiPSC lines differentiated and stained for MHC (Myosin Heavy Chain) and nuclear stain DAPI at day 50±LDN addition, 200 µm scale bar.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Expression of muscle and neuronal markers during the myogenic differentiation.</title><p>(<bold>A</bold>) PAX7 immunofluorescence staining at day 50 of the myogenic differentiation in control and BMP impaired hiPSCs (scale bar, 50 µm). (<bold>B</bold>) TUJ-1immunostaining at day 50 of differentiation (scale bar, 50 µm).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig2-figsupp1-v2.tif"/></fig></fig-group><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-66107-video1.mp4"><label>Video 1.</label><caption><title>Myotube contraction of differentiated Control (1323-2) hiPSCs.</title></caption></media><media id="video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-66107-video2.mp4"><label>Video 2.</label><caption><title>Myotube contraction of differentiated FOP (F1-1) hiPSCs.</title></caption></media><p>Since BMPs control skeletal muscle differentiation from hiPSCs (<xref ref-type="bibr" rid="bib15">Chal et al., 2016</xref>; <xref ref-type="bibr" rid="bib73">Xi et al., 2017</xref>), we investigated if genetic activation of the BMP pathway via <italic>ACVR1</italic><sup><italic>R206H</italic></sup> could alter the myogenic differentiation of hiPSCs (F1-1, F2-3, F3-2) derived from patients with FOP (<xref ref-type="bibr" rid="bib38">Matsumoto et al., 2013</xref>). All three FOP iPSC lines formed contractile myotubes with cells expressing PAX7, MYOGENIN, and DYSTROPHIN (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). <italic>PAX7</italic>, <italic>MYF5</italic>, <italic>MYOD1,</italic> and <italic>MYOGENIN</italic> (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) gene expression showed some heterogeneity among the different hiPSC lines but these differences were not statistically significant. The heterogeneity seen is likely due to the presence of other cell types in our differentiation such as neuronal cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Adding a SMAD inhibitor of the BMP pathway (LDN193189) into the differentiation protocol (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) improved the differentiation of the control hiPSC lines. LDN also improved differentiation of the FOP F3-2 (<xref ref-type="fig" rid="fig2">Figure 2F</xref>) line, which had shown lower <italic>PAX7</italic> and <italic>MYOGENIN</italic> expression (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). These findings show that individual hiPSC lines are heterogeneous in differentiation to skeletal muscle lineages, similar to other protocols (<xref ref-type="bibr" rid="bib70">Volpato and Webber, 2020</xref>), that FOP hiPSCs can form skeletal muscle cells and Hu-MuSC-like cells expressing PAX7 despite upregulation of the BMP pathway by <italic>ACVR1</italic><sup><italic>R206H</italic></sup>, and that chemical blockade of the BMP pathway can improve the formation of Hu-MuSC-like cells from the FOP iPSC line that showed the lowest efficiency.</p></sec><sec id="s2-3"><title>PAX7 expressing cells can be isolated from myogenic differentiation</title><p>To test the regenerative properties of PAX7-expressing MuSCs, we used FACS to purify HNK1<sup>-</sup>CD45<sup>-</sup>CD31<sup>-</sup> cells co-expressing CD29, CXCR4, and CD56 markers present on human PAX7<sup>+</sup> cells (<xref ref-type="bibr" rid="bib27">Garcia Steven et al., 2018</xref>; <xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–C</xref>). FACS analysis identified intermediate CD56 cells expressing high <italic>PAX7</italic> and low <italic>MYOGENIN</italic> (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C,D</xref>), consistent with Hu-MuSC expression profiles. All HNK1<sup>-</sup>CD45<sup>-</sup>CD31<sup>-</sup> CXCR4<sup>+</sup>CD29<sup>+</sup>CD56<sup>dim</sup> cells formed myotubes expressing MHC (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>) when cultured in terminal differentiation media demonstrating isolation of functional iMPCs with satellite cell-like characteristics from the cultures.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Isolation and transplantation of PAX7-expressing cells from hiPSC muscle differentiation culture.</title><p>hiPSCs were differentiated into iMPCs until day 50 and sorted via flow cytometry. (<bold>A</bold>) Gating strategy. (<bold>B</bold>) Myogenic gene expression of CD56<sup>dim</sup> and CD56<sup>hi</sup> cells. CD56<sup>dim</sup> vs CD56<sup>hi</sup>, n = 6 (3 Ctrl and 3 FOP lines) biological replicates, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001. No significant differences were found between control and FOP lines. (<bold>C</bold>) Representative human DYSTROPHIN (top, 200 µm scale bar), and human LAMIN A/C, human SPECTRIN, and PAX7 (bottom, 100 µm scale bar) immunohistochemistry of NSG mice anterior tibialis, where sorted iMPCs were transplanted. White arrows show engrafted hiPSC-derived muscle stem cells. (<bold>D</bold>) Quantification of human DYSTROPHIN fibers and human PAX7 cells at week 5 after transplant (n = 3 biological replicates). Transplantation details are in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>hiPSC-derived HNK1<sup>-</sup>CD45<sup>-</sup>CD31<sup>-</sup> CXCR4<sup>+</sup>CD29<sup>+</sup>CD56<sup>dim</sup> cell transplants.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-66107-fig3-data1-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Differentiated cell types in the myogenic differentiation varies between cell lines, sorted cells express PAX7 and can differentiate into myotubes.</title><p>(<bold>A</bold>) Representative flow cytometry profiles of negative (CD45 and CD31) and positive (CD29 and CD56) markers used to purify muscle stem cells. (<bold>B</bold>) Quantification of the percentage of cells positive for CD45, CD31, CD29, and CD56 at day 20. (n = 3 biological replicates and n = 3 technical replicates). Error bars represent mean and SD. (<bold>C</bold>) FACS plots for the single staining controls. (<bold>D</bold>) FACS analysis of the myogenic differentiation at day 50. Cells were stained for PAX7, CD29, and CD56. (<bold>E</bold>) Representative immunofluorescence staining for MHC showing of sorted iMPCs after being cultured in differentiation media for 7 days (200 µm scale bar).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Isolated iMPCs can regenerate injured mouse muscle and form human fibers</title><p>To assess iMPC regenerative capacity in vivo, we injected 1000–10,000 iMPCs derived from control or FOP hiPSCs (<xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>) into the irradiated TA muscle of NSG mice. New fibers expressing human DYSTROPHIN and PAX7 cells were found after 5 weeks, showing that iMPCs could engraft and promote muscle regeneration (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). However, the number of human fibers and human PAX7<sup>+</sup> cells remained low (<xref ref-type="fig" rid="fig3">Figure 3D</xref>) compared to primary Hu-MuSCs. While some iMPC transplants yielded up to 60 new human fibers, some did not yield any human fibers. By comparison, 2000 primary non-FOP Hu-MuSCs resulted in an average of 155 human fibers based on prior assessments using the same assay (<xref ref-type="bibr" rid="bib27">Garcia Steven et al., 2018</xref>). No significant differences between control and FOP iMPCs were identified, though some individual FOP samples showed higher engraftment (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><p>These results showed that iMPCs have engraftment potential into a muscle injury site in mice, but engraftment efficiency may be lower than primary Hu-MuSCs or be the result of differences in experimental conditions. Also, <italic>ACVR1</italic><sup><italic>R206H</italic></sup> did not significantly impact muscle fiber regeneration in this assay.</p></sec><sec id="s2-5"><title>Transcriptional profiling of iMPCs</title><p>The lower engraftment of iMPCs compared to primary Hu-MuSCs suggested that the FACS-purified population was still heterogeneous or that iMPCs do not fully recapitulate adult primary Hu-MuSCs. Single cell RNA sequencing (scRNAseq) from control (1323–2) and FOP (F3-2) iMPCs (these lines were selected based on their lower intra-line variability, <xref ref-type="fig" rid="fig2">Figure 2</xref>) were analyzed (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). Cell populations for both samples were defined by the dimension reduction technique of uniform manifold approximation and projection (UMAP) (<xref ref-type="bibr" rid="bib8">Becht et al., 2018</xref>) and unsupervised clustering with Seurat v3 package (<xref ref-type="bibr" rid="bib63">Stuart et al., 2019</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–B</xref>). Both control (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) and FOP (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>) samples had clusters expressing myogenic genes (<italic>PAX7</italic> and <italic>MYOD</italic>); mesenchymal genes (<italic>PDGFRA</italic>); and neuronal genes (<italic>SOX2</italic>) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Merged analysis to allow direct comparison identified 13 distinct clusters (<xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). Cells expressing muscle markers (<italic>PAX7</italic>, <italic>MYF5</italic>, <italic>MYOD,</italic> and <italic>MYOG</italic> [<italic>MYOGENIN</italic>]) were found in clusters 0–2 (<xref ref-type="fig" rid="fig4">Figure 4B–C</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). Mesenchymal genes (<italic>PDGFRA</italic>, <italic>ASPN</italic>, and <italic>COL1A1</italic>) were expressed in cluster 3. Cluster four consisted cells expressing retinal (<italic>OTX2</italic>) and neuroprogenitor cell (NPC) markers (<italic>SOX2</italic>, <italic>MAP2</italic>). Neuroprogenitor markers (<italic>SOX2</italic>, <italic>MAP2</italic>) and <italic>HES6</italic> were upregulated in cluster 5. Clusters 6 and 7 were made of cycling neuroprogenitor cells (<italic>MKI67</italic>, <italic>TOP2A</italic>). We also found three clusters (8-11) to be neuroepithelial cells (NECs), with cluster 10 having and increased in expression of mTor gene downstream target. Glial cells (<italic>TNC</italic>, <italic>SLC1A2</italic>) were comprised in cluster 12 (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). The frequency of muscle cells (clusters 0–2) was higher in FOP (14%, 2.5%, and 1.7%) compared to controls (4.2%, 0.5%, and 0.5%) (<xref ref-type="fig" rid="fig4">Figure 4F</xref>) suggesting that FOP hiPSCs may be more efficient at making muscle progenitor cells. Thus, FACS-purified iMPC cultures contain muscle stem/progenitor cells, but other cell types such as mesenchymal, neuronal progenitor cells, and myoblasts persist in the culture. Furthermore, the frequency of iMPCs appears to be higher in FOP vs. control cell cultures.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Single-cell RNA sequencing of HNK1<sup>-</sup>CD45<sup>-</sup>CD31<sup>-</sup>CXCR4<sup>+</sup>CD29<sup>+</sup>CD56<sup>dim</sup> cells.</title><p>(<bold>A</bold>) Schematic of differentiating hiPSCs, sorting of iMPCs, and scRNAseq. (<bold>B</bold>) UMAP visualization plots of cells combined from both control and FOP samples. Cell types were assigned based on the expression of marker genes (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), MPC (muscle progenitor cells), NPCs (neuroprogenitor cells) and NECs (neuroepithelial cells). (<bold>C</bold>) Feature expression plots showing the localization of cells expressing myogenic markers (<italic>PAX7</italic>, <italic>MYF5</italic>), mesenchymal (<italic>COL1A1</italic>), and neural cell marker (<italic>SOX2</italic>). (<bold>D</bold>) Dot plot displaying expression genes associated with myogenesis, mesenchymal and neurogenesis markers. (<bold>E</bold>) Proportion of cells per cluster for each sample.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Quality control information for each sample.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-66107-fig4-data1-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Markers expressed in sorted control and FOP HNK1<sup>-</sup>CD45<sup>-</sup>CD31<sup>-</sup> CXCR4<sup>+</sup>CD29<sup>+</sup>CD56<sup>dim</sup> cells.</title><p>(<bold>A–B</bold>) UMAP visualization plots of cells from control (<bold>A</bold>) and FOP (<bold>B</bold>). (<bold>C</bold>) Dot plot displaying expression genes associated with each cluster for the control (top) and FOP (bottom) sample. (<bold>D</bold>) UMAP visualization plots of merged samples with cells colored by samples. (<bold>E</bold>) Heat map of the top five differentially expressed genes in each cluster of the merged sample analysis.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>FACS-sorted iMPC transcriptome is heterogeneous</title><p>Typical muscle progenitor cultures are expected to contain cells undergoing expansion, differentiation, and maturation. Sub-clustering (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>) identified five new myogenic subpopulations (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). Clusters 0–3 expressed higher levels of <italic>PAX7</italic> and <italic>MYF5</italic> (markers of more quiescent MuSCs) while cluster four expressed higher levels of <italic>MYOD</italic> (<italic>or MYOD1</italic>), <italic>MYOG</italic>, <italic>SOX8,</italic> and <italic>MEF2C</italic> (markers of differentiated MuSCs/myoblasts/myocytes). Muscle stem-like cells expressing <italic>APOE</italic>, <italic>KRT17</italic>, and <italic>CAV1</italic> defined cluster 0. Quiescence markers (<italic>SPRY1</italic>, <italic>HEY1</italic>, <italic>HES1</italic>) were also highly expressed in this cluster. <italic>CDH15</italic>, a niche regulator of SCs quiescence (<xref ref-type="bibr" rid="bib28">Goel et al., 2017</xref>) was enriched in cluster 1. Cluster 1 also had increased expression of <italic>DES</italic>, <italic>CHRNA1</italic>, and <italic>MYOD1</italic> suggesting that these cells have a transcriptome resembling the profile of progenitor cells. Cluster 2 consisted of muscle stem-like cells expressing high levels of <italic>FOS</italic> (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Cell cycle (<italic>TOP2A</italic> or <italic>KI67</italic>) markers were increased in cluster 3 (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref> (left)). Cluster 3 had a higher proportion of cells in G2M and S phase (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref> (left)). The cell cycle distribution was similar in control and FOP (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref> (right)). The proportion of cells in clusters 3 and 4 were similar in both control (10% and 12.7%) and FOP (14.3% and 9%) samples. The proportion of cells in clusters 0 and 3 was higher in FOP (31.4% and 23.4%) compared to control (20% and 5.5%), while the proportion of cells in cluster two was increased in control (51.8% vs 21.9%) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Transcriptional profile of iMPCs.</title><p>(<bold>A</bold>) Identified myogenic clusters (in red) were sub-clustered from the other clusters (neurogenic and mesenchymal) and re-analyzed. UMAP of the new myogenic subclusters was generated. (<bold>B</bold>) Dot plot displaying expression of cluster defining genes. (<bold>C</bold>) Feature expression plots of myogenic markers. (<bold>D</bold>) Myogenic cells were ordered as a function of pseudotime using the Monocle package. (<bold>E</bold>) Pseudotime trajectory plot of myogenic clusters.Arrows represents the direction and major branches of the pseudotime. Branches A-C are marked with letters along the trajectories. (<bold>F</bold>) Gene plots displaying the expression of specific myogenic genes as a function of pseudotime. (<bold>G–H</bold>) Violin plots of myogenic (<bold>G</bold>) and chondro/osteogenic genes (<bold>H</bold>) that were significantly differentially expressed. Violin plot width depicts the larger probability density of cells expressing each particular gene at the indicated expression level. *, significantly different following differential expression testing using the Wilcoxon rank sum test per cluster. (<bold>I</bold>) SMAD and P38MAPK pathway markers significantly differentially expressed between control and FOP myogenic cells. p values for (<bold>G–H</bold>) are in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Differential expression analysis of control and FOP myogenic cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66107-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Analysis of the myogenic sub-clusters.</title><p>(<bold>A</bold>) Heat map of the top five differentially expressed genes in each cluster. (<bold>B</bold>) Cycle genes were scored for each cluster. Bar plot depicting the proportion of cells in G1/G0, G/2 M and S phase for each cluster (left) and for each sample (right). (<bold>C</bold>) Proportion bar graph of cells per cluster for the control and FOP samples. (<bold>D</bold>) UMAP showing the distribution of the two merged samples. (<bold>E</bold>) Violin plots of additional genes significantly differentially expressed by more than onefold and (<bold>F</bold>) Chondro/osteogenic genes per cluster and per sample (<bold>G</bold>). (<bold>H</bold>) Dot plot displaying the expression of genes associated with BMP and P38MAPK pathways for each cluster.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig5-figsupp1-v2.tif"/></fig></fig-group><p>We ordered the myogenic cells into three major branches using the Monocle analysis package (<xref ref-type="bibr" rid="bib67">Trapnell et al., 2014</xref>) based on genes that differ between clusters and constructed pseudotime differentiation trajectories (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). The pseudotime ordering of the cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) showed that cycling MuSCs (cluster 3) were located at the tip of the tree branch A while cluster 0 comprised of the most quiescent MuSCs were mainly distributed along branch A. Cells from the <italic>FOS</italic> upregulated MuSCs (cluster 2) were distributed along branch B. Cluster 1 (muscle progenitor cells) was distributed in the more proximal parts of branches B and C. Distal parts of branches B and C, were notably comprised of more mature cells from cluster 4 (myoblasts) (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). <italic>PAX7</italic> and <italic>MYF5</italic> were upregulated in branch A but downregulated in the tip of branches B and C (<xref ref-type="fig" rid="fig5">Figure 5C and E</xref>) confirming the correct cell ordering. <italic>MYOD</italic> and <italic>MYOG</italic> showed higher expression patterns early in branch B and late in branch C (<xref ref-type="fig" rid="fig5">Figure 5E and F</xref>).</p><p>Thus, hiPSC differentiation cultures contain subpopulations of iMPCs showing the expected spectrum of quiescence, activation, and differentiation with FOP cultures having a higher proportion of cells in the stem cell/progenitor and proliferating phases and fewer mature myoblasts.</p></sec><sec id="s2-7"><title>FOP iMPCs cells express increased chondro/osteogenic and ECM markers</title><p>Differential expression analysis on the transcriptional profiles of the sub-clustered myogenic cells (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A-E</xref>) was used to see if <italic>ACVR1</italic><sup><italic>R206H</italic></sup> altered transcriptional signatures. While <italic>PAX7</italic> was significantly increased in control vs. FOP cells in cluster three only, <italic>MYF5</italic> was significantly increased in FOP cells from cluster 1 compared to control cells (<xref ref-type="fig" rid="fig5">Figure 5G</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). Since Hu-MuSCs show heterogeneous levels of PAX7 and MYF5 expression (<xref ref-type="bibr" rid="bib34">Kuang et al., 2007</xref>), this suggests the <italic>ACVR1</italic><sup><italic>R206H</italic></sup> mutation may favor one sub-population over another. Interestingly, <italic>SPRY1,</italic> a known regulator of quiescence (<xref ref-type="bibr" rid="bib53">Shea et al., 2010</xref>) which decreases with age (<xref ref-type="bibr" rid="bib10">Bigot et al., 2015</xref>), was significantly downregulated in FOP cells in all the clusters, while <italic>DLK1</italic>, which act as a muscle regeneration inhibitor (<xref ref-type="bibr" rid="bib3">Andersen et al., 2013</xref>) was significantly increased in FOP cells (<xref ref-type="fig" rid="fig5">Figure 5G</xref> and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>).</p><p>Since the <italic>ACVR1</italic><sup><italic>R206H</italic></sup> mutation increases BMP pathway activity and expression of chondrogenic and osteogenic markers in multiple lineages (<xref ref-type="bibr" rid="bib5">Barruet et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Culbert et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Matsumoto et al., 2013</xref>), we examined the expression levels of extracellular matrix, fibrogenic, chondrogenic, and osteogenic genes. <italic>ITM2A</italic>, <italic>COL1A1</italic>, <italic>DCN</italic>, <italic>CD151</italic>, <italic>SPARC</italic>, and <italic>TIMP1</italic> were significantly increased in FOP cells (<xref ref-type="fig" rid="fig5">Figure 5H</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). ECM proteoglycans known to be involved in inflammation, including <italic>BGN</italic> (<xref ref-type="bibr" rid="bib45">Nastase et al., 2012</xref>) and <italic>LUM</italic> (<xref ref-type="bibr" rid="bib46">Nikitovic et al., 2014</xref>), <italic>TAGLN</italic> which regulates osteogenic differentiation (<xref ref-type="bibr" rid="bib22">Elsafadi et al., 2016</xref>), and <italic>IGBP5</italic> which is increased in aged satellite cells (<xref ref-type="bibr" rid="bib59">Soriano-Arroquia et al., 2016</xref>), were also increased in FOP cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>). We also investigated chondrogenic and osteogenic genes that have been described to be increased in other FOP cell types (<xref ref-type="bibr" rid="bib20">Culbert et al., 2014</xref>; <xref ref-type="bibr" rid="bib32">Hino et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Matsumoto et al., 2013</xref>) such as <italic>SOX9</italic>, <italic>SP7</italic>, <italic>RUNX2</italic>, <italic>ACAN,</italic> and <italic>BGLAP</italic>. Overall, those markers had very low level of expression in addition to have few cells expressing them. However, a higher number of cells expressed <italic>SOX9</italic> in FOP than control cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F-G</xref>). <italic>SP7</italic> was not found to be expressed in any of the samples or clusters.</p><p>Finally, expression of target genes of the BMP pathway (<italic>ID1</italic>, <italic>ID3</italic>, <italic>BMPs</italic>, and <italic>SMADs</italic>) and the p38MAPK pathway (<xref ref-type="fig" rid="fig5">Figure 5I</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1H</xref>) was assessed to see if activated ACVR1 altered these pathways. <italic>ID1</italic> was significantly higher in clusters 0 (MuSCs 1), 1 (MPCs), 3 (Cycling MuSCs), and 4 (Myoblasts) in control cells, while <italic>ID3</italic> was significantly higher in FOP cells clusters 1 (MPCs) and 2 (MuSC 2). In addition, the BMP/TGFβ pathway downstream target gene <italic>SMAD5</italic> was significantly higher in cluster 2 (MuSCs 2) of control cells. The p38 pathway components <italic>JUN</italic> (clusters 1, 3), <italic>JUNB</italic> (clusters 0–2), and <italic>FOS</italic> (clusters 1, 3) were significantly increased in FOP cells. Within the known ACVR1 co-receptors, <italic>BMPR2</italic> (clusters 3, 4) and <italic>ACVR2B</italic> (clusters 0, 2, 3) expression were significantly higher in control cells while <italic>ACVR2A</italic> expression was significantly higher in FOP cells (clusters 1, 4). <italic>ACVR2B</italic> was significantly higher in control cells (clusters 0, 1, 4) (<xref ref-type="fig" rid="fig5">Figure 5I</xref>). Similar to the primary FOP Hu-MuSCs (<xref ref-type="fig" rid="fig1">Figure 1</xref>), these results suggest that FOP iMPCs may have a chondrogenic/osteogenic signature, increased <italic>ID3</italic> expression, and also showed higher p38 pathway activity and higher levels of the <italic>ACVR2A</italic> co-receptor at different stages of myogenic differentiation.</p></sec><sec id="s2-8"><title>iMPC transcriptome shows similarities to primary Hu-MuSCs</title><p>Comparing the iMPC scRNAseq to primary Hu-MuSCs data of sorted satellite cells from a human vastus lateralis muscle (<xref ref-type="bibr" rid="bib7">Barruet et al., 2020</xref>) was used to identify if their lower engraftment efficiency was due to transcriptional differences. The merged data UMAP (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) showed that clusters 0–5 contained myogenic cells (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>). <italic>PAX7<sup>+</sup></italic> + were identified in clusters 0–4 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Myocyte contaminants present in the primary sorted cells constituted cluster 5. Although iMPCs expressed <italic>PAX7</italic> and <italic>MYF5</italic>, the gene expression levels were higher in primary Hu-MuSCs. In contrast, <italic>MYOD</italic> was higher in iMPCs (<xref ref-type="fig" rid="fig6">Figure 6C</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Mesenchymal cells were identified in cluster six while NPCs, NECs and Glial cells were identified in clusters 7–9, 10–12 and 13, respectively (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>iMPC transcriptional signature compared to human primary muscle stem cells.</title><p>(<bold>A–B</bold>) UMAP of cells combined from human primary muscle stem cells (vastus muscle) and the control and FOP samples. (<bold>A</bold>) UMAP showing the distribution of cells per sample, and (<bold>B</bold>) with clusters labeled. (<bold>C</bold>) Dot plot displaying expression of cluster defining genes. (<bold>D</bold>) Myogenic cells (in red) are comprised in cluster 0–5. UMAP of the myogenic clusters. (<bold>E–G</bold>) Pseudotime trajectory plot generated via Monocle analysis depicting all myogenic clusters (<bold>E</bold>) and samples (<bold>F</bold>). (<bold>G</bold>) Level of expression of ECM/osteogenic genes along the cell trajectories. (<bold>H</bold>) Heatmap representing genes that are significantly branch dependent using the BEAM analysis (<xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>) and also genes that have similar lineage-dependent expression patterns. Branches are shown in the upper right panel.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>BEAM analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66107-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Expression of myogenic markers across primary and hiPS-derived myogenic cells.</title><p>Dot plot displaying the average expression and the percent of cells expressing myogenic genes across clusters for the three merged samples.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Detailed analysis of the myogenic cell subset (cluster 0–5, <xref ref-type="fig" rid="fig6">Figure 6D</xref>) was performed using pseudotime trajectory analysis to elucidate the states of the iMPCs with respect to primary Hu-MuSCs. Cells from clusters 0, 1, and 4 were distributed along branches B and C. Myocytes ordered at the distal end of branch A. iMPCs ordered away from primary Hu-MuSCs (<italic>PAX7</italic>+) and primary myocytes (<italic>MYL1</italic>+) (<xref ref-type="fig" rid="fig6">Figure 6E–G</xref>). Branch expression analysis modeling (BEAM) allowed us to investigate significant gene that are branch-dependent in their expression (<xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). Branch A was mainly constituted of primary Hu-MuSCs while branch B consisted of iMPCs and subset of primary Hu-MuSCs, expressed significantly higher levels of genes associated with mesenchymal, fibrogenic, chondrogenic, osteogenic lineages and extracellular matrix (<xref ref-type="fig" rid="fig6">Figure 6G and H</xref>). Thus, iMPCs retained strong bi-potency compared to primary Hu-MuSCs, suggesting that iMPCs may not be as committed to the muscle lineage as primary adult muscle stem cells (<xref ref-type="bibr" rid="bib74">Xi et al., 2020</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Developing optimal strategies for skeletal muscle regeneration and repair requires a detailed understanding of how these processes are regulated. Our study uses the abnormal ACVR1 activity of FOP to dissect how the BMP/ACVR1 pathways impact skeletal muscle repair (<xref ref-type="fig" rid="fig7">Figure 7</xref>). In the case of FOP, muscle injury can trigger disease progression or severe complications. Thus, generating large numbers of human iMPCs using transgene-free protocols holds promise for understanding pathological mechanisms and finding new therapeutic targets. The findings in FOP are also likely to help inform why HO sometimes forms in other conditions of muscle injury or inflammation, including burns, CNS injury, rheumatologic disorders, trauma, and surgery (<xref ref-type="bibr" rid="bib39">Matsuo et al., 2019</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Testing the role of activated ACVR1 signaling in muscle repair.</title><p>FOP iMPCs and FOP primary human muscle stem cells are used for modeling muscle stem cell engraftment and regeneration properties.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66107-fig7-v2.tif"/></fig><p>This study revealed several novel findings, including deficiencies in the muscle repair capacity of FOP Hu-MuSCs obtained from two different subjects, abnormal production of extracellular matrix components by iMSCs and FOP Hu-MuSCs that may contribute to FOP disease progression, and important differences between primary Hu-MuSCs and iMPCs that may impact other studies. In addition, our results suggest that there are muscle specific differences in FOP Hu-MuSC repair capacity, potentially explaining why some skeletal muscles appear to be protected from developing HO.</p><p>The iMPC and primary Hu-MuSC single cell transcriptomes revealed clear subsets of cells at all stages of muscle differentiation (quiescent, activated, and differentiated). Satellite cell subtype markers e.g. <italic>COLs</italic>, <italic>DLK1</italic>, <italic>ID3</italic>, and <italic>HES1,</italic> (<xref ref-type="bibr" rid="bib7">Barruet et al., 2020</xref>) were also highly expressed in iMPCs suggesting that in vitro differentiation may favor specific subtypes of satellite cells. iMPCs also expressed high levels of mesenchymal/ECM markers, similar to that in human fetal muscle progenitor cells (<xref ref-type="bibr" rid="bib74">Xi et al., 2020</xref>). These results suggest that iMPCs may retain a more progenitor-like phenotype as compared to Hu-MuSCs. In addition, we showed that PAX7<sup>+</sup> iMPCs can engraft in muscle injury models in mice but at lower efficiency.</p><p>This iMPC system revealed that activation of the BMP pathway by the FOP <italic>ACVR1</italic><sup><italic>R206H</italic></sup> mutation induced changes that could contribute to abnormal muscle healing. As expected, the classical SMAD pathways were active in FOP cells; however, it was unexpected to find that the p38 pathway via JUN/FOS was more active in the FOP iMPCs, considering that FOP cultures had a higher proportion of cells in the stem cell/progenitor and proliferating phases. While increased SMAD activity (<xref ref-type="bibr" rid="bib11">Billings et al., 2008</xref>) or misinterpretation of the Activin A ligand (<xref ref-type="bibr" rid="bib29">Hatsell et al., 2015</xref>) occur with the <italic>ACVR1</italic><sup><italic>R206H</italic></sup> mutation, abnormal p38 signaling may be critical in some cell types like macrophages (<xref ref-type="bibr" rid="bib6">Barruet et al., 2018</xref>). Since p38 is a major regulator of Hu-MuSC function (<xref ref-type="bibr" rid="bib52">Segalés et al., 2016</xref>) and has been associated with inflammation and ECM accumulation in aged muscle (<xref ref-type="bibr" rid="bib19">Cosgrove et al., 2014</xref>), further studies are needed to determine how this p38 signaling contributes to satellite cell subtype specification (<xref ref-type="bibr" rid="bib7">Barruet et al., 2020</xref>) and affect healing in FOP.</p><p>Importantly, our iMPC and Hu-MuSC transplant studies showed no HO in the recipient mice, consistent with prior FOP genetic studies (<xref ref-type="bibr" rid="bib21">Dey et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Lees-Shepard et al., 2018</xref>) describing that other cell types may be directly responsible for bone formation. Indeed, several reports have suggested fibro/adipogenic progenitors (FAPs) as a candidate cell population to FOP pathogenesis. Interestingly, there are functional cross-talk between satellite cells and FAPs which is critical for muscle repair in homeostasis, disease, and aging contexts (<xref ref-type="bibr" rid="bib9">Biferali et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Farup et al., 2015</xref>; <xref ref-type="bibr" rid="bib36">Lukjanenko et al., 2019</xref>; <xref ref-type="bibr" rid="bib71">Wosczyna and Rando, 2018</xref>). However, FOP iMPCs showed increased chondrogenic/osteogenic and ECM gene expression, a feature seen in other bone-related cell types in FOP (<xref ref-type="bibr" rid="bib5">Barruet et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Culbert et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Lees-Shepard et al., 2018</xref>). Thus, one possibility would be for FOP Hu-MuSCs to further contribute to HO formation indirectly by modulation of the osteogenic environment such as contributing to changes in muscle stiffness, as previously reported in FOP mice (<xref ref-type="bibr" rid="bib30">Haupt et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Stanley et al., 2019</xref>). This has also been reported in aged muscle, which show increased myofiber stiffness due to increased ECM deposition (<xref ref-type="bibr" rid="bib33">Hwang and Brack, 2018</xref>). In addition, while our results suggest no major differences or possibly a slight increase in the ability to form skeletal muscle progenitors, activated ACVR1 by the <italic>R206H</italic> mutation decreased (but did not abrogate) in vitro formation of mature myoblasts of FOP hiPSCs and in vivo muscle repair after transplant of primary FOP Hu-MuSCs.</p><p>Comparing primary FOP Hu-MuSCs from muscles that develop HO (biceps) and non-affected muscle (diaphragm) suggests that the source of the Hu-MuSCs may impact engraftment efficiency. The re-injury model showed that engraftment of Hu-MuSCs from FOP biceps, but not from diaphragm, remained significantly decreased. Thus, it is intriguing to consider that the clinical sparing of the diaphragm from HO in patients with FOP may result from a less impaired or unimpaired muscle repair process in diaphragm satellite cells. Further delineation of muscle-specific Hu-MuSC properties will be revealing to understand this observation. Our finding that primary FOP Hu-MuSCs have lower engraftment ability provides a potential explanation for the poor skeletal muscle repair observed in patients with FOP (<xref ref-type="bibr" rid="bib56">Shore, 2012</xref>). However, the FOP and control iMPCs showed no major differences in engraftment, possibly due to decreased assay sensitivity from the lower engraftment efficiency of iMPCs in general, which could be explained by iMPCs being more immature than primary Hu-MuSCs, the presence of cell contaminants after isolation, or that iMPCs represent a subtype of cells that may be more reflective of non-ossifying skeletal muscle like diaphragm.</p><p>This study has several limitations. Our transplant experiments used immunocompromised mice where mature B and T cells are absent and macrophages are defective (<xref ref-type="bibr" rid="bib58">Shultz et al., 2005</xref>). This may dampen the engraftment/regenerative phenotypes, particularly as immune cells are important in muscle regeneration (<xref ref-type="bibr" rid="bib25">Furrer and Handschin, 2017</xref>) and there is growing awareness of the role of the immune system in the pathogenesis of FOP (<xref ref-type="bibr" rid="bib6">Barruet et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Convente et al., 2018</xref>). Also, while our FACS strategy can isolate Hu-MuSCs and iMPCs without the need of transcription factors or markers, we noted that the engraftment efficiency still varied among the iMPC lines despite FACS purification. This heterogeneity is an ongoing problem among all published iMPC protocols to date. In our case, this was counter-balanced by our consistent findings across multiple lines and between iMPCs and the availability of primary Hu-MuSCs despite the absence of isogenic control and FOP lines. Although our primary cell studies were limited by the rarity of FOP (estimated at 1 in 1.4 million people) and even rarer suitable cadaveric samples where we were only able to obtain Hu-MSCs from two FOP subjects, the combination of iPSC-derived lineages with the rare primary samples provided multiple avenues for supporting our conclusions. Finally, the <italic>ACVR1</italic><sup><italic>R206H</italic></sup> mutation increases BMP signaling but also introduces neofunction to Activin A. Our studies are not able to distinguish between these two contributing pathways. Our finding of increased p38 activity in the FOP iMPCs was also seen in FOP subject monocyte-derived macrophages (<xref ref-type="bibr" rid="bib6">Barruet et al., 2018</xref>), suggesting that this alternate signaling pathway by ACVR1 should also be investigated further. Future studies, including the use of isogenic control lines, testing of neutralizing antibodies to directly target the ACVR1<sup>WT</sup> or ACVR1<sup>R206H</sup> receptors, and the use of other small molecule inhibitors of pathways downstream of ACVR1 (e.g. p38 or SMAD), will help elucidate the different factors that contribute to the hiPSC-line specific effects, including potential roles for disease modifier genes or BMP pathway modulators.</p><p>This study shows that human iPSC-derived muscle progenitor cells can be a valuable tool to model musculoskeletal diseases of skeletal muscle injury and repair. Correlating the findings in iMPCs with primary Hu-MuSCs revealed an indirect role for skeletal muscle progenitors in HO formation, as well as potential subtypes of Hu-MuSCs that could contribute to skeletal muscle specific regenerative capacity (<xref ref-type="fig" rid="fig7">Figure 7</xref>). These studies highlight the importance of skeletal muscle regeneration in disease pathogenesis and establish a foundation for understanding how skeletal muscle repair and osteogenesis are linked.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.jax.org/strain/005557">https://www.jax.org/strain/005557</ext-link></td><td align="left" valign="bottom">MGI:3577020</td><td align="char" char="ndash" valign="bottom">8–12 weeks old</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human RT-PCR Primers</td><td align="left" valign="bottom">Applied Biosystems Taqman Assays</td><td align="left" valign="bottom"><italic>ACTB</italic>Hs01060665_g1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human RT-PCR Primers</td><td align="left" valign="bottom">Applied Biosystems Taqman Assays</td><td align="left" valign="bottom"><italic>DYSTROPHIN</italic>Hs007758098_m1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human RT-PCR Primers</td><td align="left" valign="bottom">Applied Biosystems Taqman Assays</td><td align="left" valign="bottom"><italic>PAX7</italic>Hs00242962_m1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human RT-PCR Primers</td><td align="left" valign="bottom">Applied Biosystems Taqman Assays</td><td align="left" valign="bottom"><italic>CD56</italic>Hs00941830_m1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human RT-PCR Primers</td><td align="left" valign="bottom">Applied Biosystems Taqman Assays</td><td align="left" valign="bottom"><italic>MYOD1</italic>Hs00159528_m1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human RT-PCR Primers</td><td align="left" valign="bottom">Applied Biosystems Taqman Assays</td><td align="left" valign="bottom"><italic>MYF5</italic>Hs00929416_g1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human RT-PCR Primers</td><td align="left" valign="bottom">Applied Biosystems Taqman Assays</td><td align="left" valign="bottom"><italic>MYOGENIN</italic> Hs01072232_m1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human RT-PCR Primers</td><td align="left" valign="bottom">Applied Biosystems Taqman Assays</td><td align="left" valign="bottom"><italic>COL1A1</italic>Hs01076780_g1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human RT-PCR Primers</td><td align="left" valign="bottom">Applied Biosystems Taqman Assays</td><td align="left" valign="bottom"><italic>ID1</italic>Hs03676575_s1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human RT-PCR Primers</td><td align="left" valign="bottom">Applied Biosystems Taqman Assays</td><td align="left" valign="bottom"><italic>ID3</italic>Hs00954037_g1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human DYSTROPHIN (mouse monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2618157">AB_2618157</ext-link></td><td align="left" valign="bottom">IF(1:10)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human/Mouse DYSTROPHIN (mouse monoclonal)</td><td align="left" valign="bottom">Thermofisher</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10978300">AB_10978300</ext-link></td><td align="left" valign="bottom">IF(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human/Mouse PAX7 (mouse monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_528428">AB_528428</ext-link></td><td align="left" valign="bottom">IF(1:10)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human/Mouse MHC (mouse monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2147781">AB_2147781</ext-link></td><td align="left" valign="bottom">IF(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LAMININ (rabbit polyclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_477163">AB_477163</ext-link></td><td align="left" valign="bottom">IF(1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human SPECTRIN (mouse monoclonal)</td><td align="left" valign="bottom">Leica Microsystems</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_442135">AB_442135</ext-link></td><td align="left" valign="bottom">IF(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human LAMIN A/C (mouse monoclonal)</td><td align="left" valign="bottom">Vector Laboratories</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2336546">AB_2336546</ext-link></td><td align="left" valign="bottom">IF(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD31 (Beads) (Mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="char" char="hyphen" valign="bottom">130-091-935</td><td align="left" valign="bottom">2 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD45 (Beads, mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2783001">AB_2783001</ext-link></td><td align="left" valign="bottom">5 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD31 AF450(WM-59, mouse monoclonal)</td><td align="left" valign="bottom">Ebioscience</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10854276">AB_10854276</ext-link></td><td align="left" valign="bottom">5 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD34 eFluor450(4H11, mouse monoclonal)</td><td align="left" valign="bottom">Ebioscience</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10733282">AB_10733282</ext-link></td><td align="left" valign="bottom">5 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD45 AF450(30-F11, mouse monoclonal)</td><td align="left" valign="bottom">Ebioscience</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_1518806">AB_1518806</ext-link></td><td align="left" valign="bottom">5 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD29 FITC(TS2/16, mouse monoclonal)</td><td align="left" valign="bottom">Ebioscience</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2043830">AB_2043830</ext-link></td><td align="left" valign="bottom">8 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Recombinant human anti-CD56 APC-vio-770 (REA196)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2733136">AB_2733136</ext-link></td><td align="left" valign="bottom">8 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CXCR4 PE(12G5, mouse monoclonal)</td><td align="left" valign="bottom">Ebioscience</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10669164">AB_10669164</ext-link></td><td align="left" valign="bottom">8 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human HNK1 PE (TB01, mouse monoclonal)</td><td align="left" valign="bottom">Ebioscience</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10804531">AB_10804531</ext-link></td><td align="left" valign="bottom">5 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD45 PE(30-F11, mouse monoclonal)</td><td align="left" valign="bottom">Ebioscience</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_465668">AB_465668</ext-link></td><td align="left" valign="bottom">5 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD31 PE(390, mouse monoclonal)</td><td align="left" valign="bottom">Ebioscience</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_465632">AB_465632</ext-link></td><td align="left" valign="bottom">5 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD56 APC (CMSSB, mouse monoclonal)</td><td align="left" valign="bottom">Ebioscience</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10854573">AB_10854573</ext-link></td><td align="left" valign="bottom">5 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CXCR4 PE-Cy7 (12G5, mouse monoclonal)</td><td align="left" valign="bottom">Ebioscience</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_1659706">AB_1659706</ext-link></td><td align="left" valign="bottom">5 μl</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FcR block</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2892112">AB_2892112</ext-link></td><td align="left" valign="bottom">5 μl</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom">GraphPad Prism (<ext-link ext-link-type="uri" xlink:href="https://graphpad.com">https://graphpad.com</ext-link>)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCr_002798">SCr_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Seurat (3.1.5)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://satijalab.org/seurat/">https://satijalab.org/seurat/</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_007322">SCR_007322</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_021002">SCR_021002</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Monocle (2.12.0)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://cole-trapnell-lab.github.io/monocle-release/">http://cole-trapnell-lab.github.io/monocle-release/</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_016339">SCR_016339</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">cellranger</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/feature-bc">https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/feature-bc</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_021002">SCR_021002</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com">https://www.flowjo.com</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture and differentiation</title><p>Pluripotent hiPSC lines derived from control and FOP fibroblasts (<xref ref-type="bibr" rid="bib38">Matsumoto et al., 2013</xref>; <xref ref-type="bibr" rid="bib60">Spencer et al., 2014</xref>) were cultured in mTeSR1 medium (StemCell Technologies) on irradiated SNL feeder cells (<xref ref-type="bibr" rid="bib42">McMahon and Bradley, 1990</xref>) as described previously. hiPSCs were passaged at least once on Matrigel (Corning)-coated plates (150–300 µg/ml) to remove the SNLs before use in differentiation assays. ROCK inhibitor Y-27632 (10 µM, StemCell Technologies) was added to mTeSR1 when cells were split and removed the following day.</p><p>hiPSC lines were differentiated into skeletal muscle cells using modifications based on prior protocols (<xref ref-type="bibr" rid="bib15">Chal et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Shelton et al., 2014</xref>). Our hiPSC lines differentiated better with a lower cell number seeding and a longer time of recovery between the seeding and the start of the differentiation (2 days, data not shown). Cells were seeded at 7.5 × 10<sup>5</sup> cells per well of a 12-well plate on Matrigel two days before the differentiation medium (E6 medium, supplemented with either 10 µM CHIR99021 (Tocris) for 2 days or with 3 µM CHIR99021 and 0.5 µM LDN193189 for six days). Cells were then grown in un-supplemented E6 media until day 12, then changed to StemPro-34 media supplemented with 10 ng/ml bFGF until day 20. The medium was then replaced by E6 medium until day 35, when DMEM/F12 supplemented with N2 (Gibco) and Insulin-Transferrin-Selenium (ITS-A, 100 X Gibco) was added. Media was changed daily until harvest at day 50. After sorting, cells were plated in satellite cell media [DMEM/F12 (Gibco), 20 % FBS (Hyclone), 1 X ITS (Gibco), 1 X Penicillin/ Streptomycin (Gibco)] for further functional assays (<xref ref-type="fig" rid="fig2">Figure 2A and F</xref>). Once cells reached confluence, cells were cultured in differentiation media (DMEM, 2 % horse serum, 1 X Penicillin/ Streptomycin; Gibco).</p></sec><sec id="s4-2"><title>Cell lines</title><p>Pluripotent hiPSC lines were previously derived from the following control and FOP fibroblasts (<xref ref-type="bibr" rid="bib38">Matsumoto et al., 2013</xref>; <xref ref-type="bibr" rid="bib60">Spencer et al., 2014</xref>): FF-WT-BJ (Foreskin, Stemgent 08–0027), HDF-WT-1323 (Fibroblast, Cell Applications 1323), HDF-WTc (Skin biopsies obtained from donors), HDF-FOP1 (Skin Fibroblast, Corrielle GM00513), HDF-FOP2 (Skin Fibroblast, Corrielle GM00783), and HDF-FOP3 (Skin biopsies obtained from donors). All hiPSCs are tested periodically for mycoplasma and have been negative to date. Cell lines are yearly authenticated using DNA fingerprinting.</p></sec><sec id="s4-3"><title>Flow cytometry</title><p>HNK1<sup>-</sup>CD45<sup>-</sup>CD31<sup>-</sup>CXCR4<sup>+</sup>CD29<sup>+</sup>CD56<sup>dim</sup> cells were sorted from skeletal muscle differentiation of control and FOP hiPSCs. Human primary satellite cells were isolated and sorted as described (<xref ref-type="bibr" rid="bib27">Garcia Steven et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Garcia et al., 2017</xref>). Human muscle was freshly harvested and stored in DMEM with 30 % FBS at 4 °C overnight or for two extra days (delay due to shipping). Muscle samples were digested, erythrocytes were lysed, and hematopoietic and endothelial cells were depleted with magnetic column depletion using CD31, CD34, and CD45 (eBioscience). Cells were further gated as described in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> and sorted for CXCR4<sup>+</sup>/CD29<sup>+</sup>/CD56<sup>+</sup> and collected for subsequent experimentation.</p><p>For the staining, cells were treated with Accutase for 20 min at 37 C, washed with FACS buffer, and stained for HNK1-PE, CD45-PE, CD31-PE, CD56-APC, CXCR4-PE-Cy7, and CD29-FITC (eBioscience). HNK1<sup>-</sup>CD45<sup>-</sup>CD31<sup>-</sup> cells [to select against neuronal cells (HNK1, Human Natural Killer-1) (<xref ref-type="bibr" rid="bib17">Choi et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Hicks et al., 2018</xref>), hematopoietic cells (CD45), and endothelial cells (CD31)], co-expressing CD29, CXCR4, and intermediate CD56, markers present on human PAX7<sup>+</sup> cells (<xref ref-type="bibr" rid="bib27">Garcia Steven et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Garcia et al., 2017</xref>; <xref ref-type="bibr" rid="bib75">Xu et al., 2015</xref>) were sorted with a FACSAriaIII (BD Biosciences) and Sytox Blue (Life Technologies) was used as a viability marker. Alternatively, cells were permeabilized and fixed (Fix/Perm Buffer Set, BioLegend). Fixed cells were first incubated with primary antibodies PAX7 (DSHB), CD29 (BD Biosciences), and CD56 (BD Biosciences) following by secondary antibodies (Alexa350-conjugated goat anti-mouse IgG, Alexa488-conjugated goat anti-rat IgG and Alexa546-conjugated donkey anti-goat IgG, Life Technologies).</p></sec><sec id="s4-4"><title>Animal care and transplantation studies</title><p>All mouse studies were performed using protocols approved by the UCSF Institutional Animal Care and Use Committee. Mice were either bred and housed in a pathogen-free facility at UCSF or purchased from The Jackson Laboratory. Eight to 12-week-old NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were randomized to all experimental groups by sex and littermates. Each mouse was irradiated with 18 Gy before transplantation. Isolated primary human satellite cells (Hu-MuSCs) or iMPCs were injected with 50 µl 0.5 % bupivacaine directly into the tibialis anterior (TA) muscle of one leg as described (<xref ref-type="bibr" rid="bib27">Garcia Steven et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Garcia et al., 2017</xref>). The TA for each mouse was harvested at week 5 or week 10 after transplantation and frozen in O.C.T. compound in 2-methylbutane chilled in liquid nitrogen. Serial 6 µm transverse frozen sections were analyzed or stored at –80 °C.</p><p>Collected tibialis anterior frozen cross sections were fixed in 4 % PFA for 10 min at room temperature, washed with PBST PBS with 0.1 % Tween-20 (Sigma-Aldrich), and blocked in PBS with 10 % goat serum for 1 hr at room temperature. Slides were then incubated 4 hrs at room temperature with the following: mouse monoclonal anti-human DYSTROPHIN (DSHB), mouse monoclonal IgG1 anti-PAX7 (DSHB), rabbit polyclonal anti-Laminin (Sigma-Aldrich), mouse monoclonal IgG2b anti-human SPECTRIN (Leica Microsystems), and mouse monoclonal IgG2b anti-human LAMIN A/C (Vector Laboratories). After PBST wash, slides were incubated with the following secondary antibodies: Alexa Fluor 555 goat anti-mouse IgG, Alexa Fluor 594 goat anti-mouse IgG1, Alexa Fluor 488 goat anti-mouse IgG2b, and Alexa Fluor 647 goat anti-rabbit (Life Technologies). Finally, sections were mounted with VECTASHIELD mounting media with DAPI (Vector Laboratories). All samples were examined using a Leica upright or DMi8 Leica microscope. Sections with the most human fibers were used for human DYSTROPHIN and PAX7 quantification for each condition, as described below.</p><p>Cell Immunostaining and NSG Tibialis Anterior Analysis iMPCs were fixed with 4%PFA/PBS for 10 min at room temperature, permeabilized with 0.1%Triton-100X (Sigma-Aldrich), and blocked with 5 % BSA (Sigma-Aldrich). Cells were stained overnight with primary antibodies for PAX7, MYOGENIN, DYSTROPHIN, and MHC. Cells were then incubated for 1 hr at room temperature in the dark with secondary antibodies Alexa488-conjugated goat anti-mouse IgG and Alexa546-conjugated goat anti-mouse IgG (Invitrogen). Nuclei were stained with DAPI (Sigma-Aldrich). Images were taken on a Nikon Eclipse E800 or Leica DMI 4000B.</p></sec><sec id="s4-5"><title>Immunohistochemistry and immunofluorescence of human muscle samples</title><p>Human muscle samples were fixed in neutral buffered formalin for 24 hr and then placed in 70 % ethanol for at least 24 hr. The sample with heterotopic bone was decalcified in 10 % EDTA (pH 7.2–7.4) before paraffin embedding and sectioning. Sections were stained with hematoxylin and eosin (J. David Gladstone Institutes Histology Core) or for alcian blue (pH 1.0) for cartilage and nuclear red stain for nuclei.</p><p>Freshly harvested human muscle was stored in DMEM with 30 % FBS at 4 °C, or snap in frozen in O.C.T. compound in 2-methylbutane chilled in liquid nitrogen. Serial 6 µm transverse frozen sections were analyzed or stored at –80 °C and processed similarly to the mouse TA samples above. Sections were stained with PAX7 (DSHB) and mouse monoclonal anti-Collagen Type I (Millipore-Sigma). Details about specimens are in the <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p></sec><sec id="s4-6"><title>RT-PCR and quantitative analysis</title><p>Tissues were collected in TRI Reagent (Sigma-Aldrich) to isolate total RNA using the Arcturus PicoPure RNA kit (Applied Biosystems) as previously described for small samples (<xref ref-type="bibr" rid="bib50">Schepers et al., 2012</xref>). A total of 0.2–0.5 µg of RNA were transcribed into cDNA with VeriScript cDNA synthesis kit (Affymetrix). cDNA was then pre-amplified with GE PreAmp Master Mix (Fluidigm Inc). Real-time quantitative PCR was performed in triplicated with either VeriQuest Probe qPCR Master Mix (Affymetrix) or Taqman Universal PCR Master Mix (Life Technologies) on either a Viia7 thermocycler (Life Technologies) or on a BioMark 48.48 dynamic array nanofluidic chip (Fluidigm, Inc) according to manufacturers’ instructions. <italic>ACTB</italic> was used for normalization as endogenous control.</p><p>Single cell RNA Sequencing and Analysis scRNAseq was performed using the Chromium Single Cell 3' Reagent Version 2 Kit from 10 X Genomics. 45,000 (FOP) and 30,000 (control) HNK1<sup>-</sup>CD45<sup>-</sup>CD31<sup>-</sup> CXCR4<sup>+</sup>CD29<sup>+</sup>CD56<sup>dim</sup> cells isolated from the iMPC differentiations were loaded onto one well of a 10X chip to produce Gel Bead-in-Emulsions (GEMs). GEMs underwent reverse transcription to barcode RNA before cleanup and cDNA amplification. Libraries were prepared with the Chromium Single Cell 3' Reagent Version 2 Kit. Each sample was sequenced on 1 lane of the NovaSeq 6,000 S4. Sequencing reads were processed with Cell Ranger version 2.0.0. using the human reference transcriptome GRCh38. The estimated number of cells, mean reads per cell, median genes per cells, median UMI (Unique Molecular Identifier) counts per cells as well as other quality control information are summarized in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>. Gene-barcoded matrices were analyzed with the R package Seurat v3.1.5 (<xref ref-type="bibr" rid="bib49">Satija et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Stuart et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Team, 2014</xref>; <xref ref-type="bibr" rid="bib76">Zheng et al., 2017</xref>). Gene core matrices from single cell RNA sequencing of primary human satellite cells isolated from a vastus muscle (<xref ref-type="bibr" rid="bib7">Barruet et al., 2020</xref>) was used when comparing the transcriptional profile of hiPS-derived HNK1<sup>-</sup>CD45<sup>-</sup>CD31<sup>-</sup> CXCR4<sup>+</sup>CD29<sup>+</sup>CD56<sup>dim</sup> cells. For the comparison with primary Hu-MuSCs, hiPSC-derived cell sequencing reads were re-aligned using the human reference transcriptome hg19. Cells with fewer than 500 genes, greater than 5,000 genes and genes expressed in fewer than five cells were not included in the downstream analyses. Cells with more than 10 % mitochondrial counts were filtered out. Samples were normalized with NormalizeData using default settings. The FindVariableFeatures function was used to determine subset of feature that exhibit high cell-to-cell variation in each dataset based on a variance stabilizing transformation (‘vst’). We used the default setting returning 2000 feature per dataset. These were used for downstream analysis. In the case of the merged data analysis samples were combined utilizing the FindIntegrationAnchors function with the ‘dimensionality’ set at 30. Then, we ran these ‘anchors’ to the IntegratData function for batch correction for all cells enabling them to be jointly analyzed. The resulting outputs were scaled mitochondrial contamination regressed out with the ScaleData function. In addition, while we didn’t regress out heterogeneity associated with cell cycle stage since it is an important factor in determining the state of quiescence of our sorted human muscle stem cells, we regressed out differences between G2/M and S cell cycle stage. PCA was performed with RunPCA, and significant PCs determined based on the Scree plot utilizing the function PCElbowPlot. The resolution parameter in FindClusters was adjusted to 0.5. Clusters were visualized by UMAP with Seurat’s RunUMAP function. We performed differential gene-expression utilizing Seurat v3’s FindMarkers function with default settings which utilizes the Wilcoxon rank-sum test to calculate adjusted p values for multiple comparisons. We used the CellCycleScoring function to assign score based on the expression of G2/M and S phase markers (<xref ref-type="bibr" rid="bib48">Regev et al., 2017</xref>). Myogenic cells were further analyzed by sub-clustering using the subset function. We then use the FindNeighbors (dims = 15) and FindClusters (resolution = 0.4) functions on the myogenic cell subset of the merged hiPSCs samples only to identify sub-clusters corresponding to different myogenic states. To order the cells in pseudotime based on their transcriptional similarity we used Monocle 2.12. Variable genes from Seurat analysis were used as input and clusters were projected onto the minimum spanning tree after ordering. Gene expression patterns were plotted with plot_genes_branched_heatmap, plot_genes_branched_pseudotime, and plot_multiple_branches_pseudotime. The BEAM (branch expression analysis modeling) function was used to score gene significance in a branch-dependent manner. Cells were re-ordered using the orderCells function to set branch A (myocytes) in <xref ref-type="fig" rid="fig6">Figure 6H</xref> as the ‘root-state’. This allowed us to determine genes that were significantly branch dependent in branch A (mainly Hu-MuSCs) vs branch B (hiPS-derived cells) using the BEAM analysis.</p></sec><sec id="s4-7"><title>Statistical analysis</title><p>The data were analyzed utilizing GraphPad Prism v.7 software (GraphPad) using one-way (transplant) and two-way ANOVA with post hoc Tukey’s or Sidak’s multiple comparison test (gene expression). The Sidak test was used when comparing means between control and FOP, and the Tukey test was used when means of both control and FOP were compared together with other groups for the gene expression data. For the transplantation studies, at least three mice were used per group. At least three biological replicates were performed for each experiment unless indicated otherwise. All error bars are depicted as standard deviation, p-values are (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001).</p></sec><sec id="s4-8"><title>Human specimen procurement</title><p>Human samples were collected through the UCSF Biospecimens and Skeletal Tissues for Rare and Orphan Disease Genetics (BSTROnG) Biobank, using protocols approved by the UCSF Institutional Review Board. All participants provided written consent. For the transplantation studies (<xref ref-type="fig" rid="fig1">Figure 1D–H</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), biopsy of the control subject was obtained from a 44 yo female healthy individual undergoing surgery at UCSF, and the muscle from the FOP patient was obtained at autopsy from a 55 yo female. Written informed consent was obtain from all subjects or their families.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>ECH receives clinical trial research funding from Clementia Pharmaceuti-cals, an Ipsen company, and Neurocrine Biosciences, Inc., through his institution. ECH received prior funding from Regeneron Pharmaceuticals, through his institution. ECH serves in an unpaid capacity on the international FOP Association Medical Registry Advisory Board, on the International Clinical Council on FOP, and on the Fibrous Dysplasia Foundation Medical Advisory Board. These activities pose no conflicts for the presented research</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Validation</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Software</p></fn><fn fn-type="con" id="con7"><p>Clinical samples, Clinical samples, Conceptualization, Funding acquisition, Resources, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Clinical samples, Clinical samples, Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Human samples were collected through the University of California - San Francisco Biospecimens and Skeletal Tissues for Rare and Orphan Disease Genetics (BSTROnG) Biobank, using protocols approved by the UCSF Institutional Review Board (10-03053 and 11-06711). All participants provided written consent, which includes consent to collect, use, and publish research data.</p></fn><fn fn-type="other"><p>All mouse studies were performed using protocols approved by the UCSF Institutional Animal Care and Use Committee. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (AN181101-02A) of the University of California, San Francisco.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-66107-transrepform1-v2.docx"/></supplementary-material><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>hiPSCs samples integration.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-66107-supp1-v2.zip"/></supplementary-material><supplementary-material id="scode2"><label>Source code 2.</label><caption><title>Myogenic sub-clustering.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-66107-supp2-v2.zip"/></supplementary-material><supplementary-material id="scode3"><label>Source code 3.</label><caption><title>Pseudotime analyses.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-66107-supp3-v2.zip"/></supplementary-material><supplementary-material id="scode4"><label>Source code 4.</label><caption><title>Primary Hu-MuSCs/hiPSCs integration.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-66107-supp4-v2.zip"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Sequencing data have been deposited in GEO under accession codes GSE151918. All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 4,5,6. The dataset used for the primary Hu-MuSCs can be found here: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7272/Q65X273X">https://doi.org/10.7272/Q65X273X</ext-link>. Detailed scripts can be found at <ext-link ext-link-type="uri" xlink:href="https://github.com/EmilieB12/FOP_muscle/tree/main">https://github.com/EmilieB12/FOP_muscle/tree/main</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:rev:2c30ff4ef2608c0a44360047e54b9ad2d3017d0c">https://archive.softwareheritage.org/swh:1:rev:2c30ff4ef2608c0a44360047e54b9ad2d3017d0c</ext-link>) or in Source code 1–4.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Barruet</surname><given-names>E</given-names></name><name><surname>Garcia</surname><given-names>SM</given-names></name><name><surname>Jake Wu</surname><given-names>J</given-names></name><name><surname>Morales</surname><given-names>BM</given-names></name><name><surname>Stanley Tamaki</surname><given-names>S</given-names></name><name><surname>Moody</surname><given-names>T</given-names></name><name><surname>Pomerantz</surname><given-names>JH</given-names></name><name><surname>Hsiao</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Control and FOP Human iPSC derived myogenic cell single cell RNA sequencing</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151918">GSE151918</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Pomerantz</surname><given-names>JH</given-names></name><name><surname>Barruet</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Functionally heterogeneous human satellite cells identified by single cell RNA sequencing</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.7272/Q65X273X</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank Kelly Wentworth and Samuel Kou for their assistance collecting the autopsy samples and Francesco Tedesco for his technical support and discussion on the AFM grant. This work was supported by a NIH/NIAMS R01AR066735 to ECH, a French Muscular Association (AFM-Telethon) Trampoline grant to ECH and EB, the Radiant Hope Foundation to ECH, and the UCSF Cohort Development Grant to ECH; the California Institute for Regenerative Medicine Fellowship Program to UCSF (TG2-01153) to EB, and the UCSF Program for Breakthrough Biomedical Research (PBBR) to EB; and the NIH R01AR072638-03 to JHP. Finally, the authors would like to thank the patients and their families for their generous specimen donations.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Loder</surname><given-names>S</given-names></name><name><surname>Brownley</surname><given-names>C</given-names></name><name><surname>Cholok</surname><given-names>D</given-names></name><name><surname>Mangiavini</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Breuler</surname><given-names>C</given-names></name><name><surname>Sung</surname><given-names>HH</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Ranganathan</surname><given-names>K</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Tompkins</surname><given-names>R</given-names></name><name><surname>Herndon</surname><given-names>D</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Jumlongras</surname><given-names>D</given-names></name><name><surname>Olsen</surname><given-names>BR</given-names></name><name><surname>Davis</surname><given-names>TA</given-names></name><name><surname>Mishina</surname><given-names>Y</given-names></name><name><surname>Schipani</surname><given-names>E</given-names></name><name><surname>Levi</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification</article-title><source>PNAS</source><volume>113</volume><fpage>E338</fpage><lpage>E347</lpage><pub-id pub-id-type="doi">10.1073/pnas.1515397113</pub-id><pub-id pub-id-type="pmid">26721400</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Tanoury</surname><given-names>Z</given-names></name><name><surname>Rao</surname><given-names>J</given-names></name><name><surname>Tassy</surname><given-names>O</given-names></name><name><surname>Gobert</surname><given-names>B</given-names></name><name><surname>Gapon</surname><given-names>S</given-names></name><name><surname>Garnier</surname><given-names>J-M</given-names></name><name><surname>Wagner</surname><given-names>E</given-names></name><name><surname>Hick</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name><name><surname>Gussoni</surname><given-names>E</given-names></name><name><surname>Pourquié</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Differentiation of the human PAX7-positive myogenic precursors/satellite cell lineage in vitro</article-title><source>Development</source><volume>147</volume><elocation-id>e12</elocation-id><pub-id pub-id-type="doi">10.1242/dev.187344</pub-id><pub-id pub-id-type="pmid">32541004</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>DC</given-names></name><name><surname>Laborda</surname><given-names>J</given-names></name><name><surname>Baladron</surname><given-names>V</given-names></name><name><surname>Kassem</surname><given-names>M</given-names></name><name><surname>Sheikh</surname><given-names>SP</given-names></name><name><surname>Jensen</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dual role of delta-like 1 homolog (DLK1) in skeletal muscle development and adult muscle regeneration</article-title><source>Development</source><volume>140</volume><fpage>3743</fpage><lpage>3753</lpage><pub-id pub-id-type="doi">10.1242/dev.095810</pub-id><pub-id pub-id-type="pmid">23946446</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>A</given-names></name><name><surname>Choudhari</surname><given-names>R</given-names></name><name><surname>Alexander</surname><given-names>AJ</given-names></name><name><surname>Allam</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Heterotopic ossification post COVID-19: Report of two cases</article-title><source>Radiology Case Reports</source><volume>16</volume><fpage>404</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.radcr.2020.12.002</pub-id><pub-id pub-id-type="pmid">33354272</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barruet</surname><given-names>E</given-names></name><name><surname>Morales</surname><given-names>BM</given-names></name><name><surname>Lwin</surname><given-names>W</given-names></name><name><surname>White</surname><given-names>MP</given-names></name><name><surname>Theodoris</surname><given-names>CV</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Urrutia</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>SA</given-names></name><name><surname>Srivastava</surname><given-names>D</given-names></name><name><surname>Hsiao</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling</article-title><source>Stem Cell Research &amp; Therapy</source><volume>7</volume><elocation-id>e115</elocation-id><pub-id pub-id-type="doi">10.1186/s13287-016-0372-6</pub-id><pub-id pub-id-type="pmid">27530160</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barruet</surname><given-names>E</given-names></name><name><surname>Morales</surname><given-names>BM</given-names></name><name><surname>Cain</surname><given-names>CJ</given-names></name><name><surname>Ton</surname><given-names>AN</given-names></name><name><surname>Wentworth</surname><given-names>KL</given-names></name><name><surname>Chan</surname><given-names>TV</given-names></name><name><surname>Moody</surname><given-names>TA</given-names></name><name><surname>Haks</surname><given-names>MC</given-names></name><name><surname>Ottenhoff</surname><given-names>TH</given-names></name><name><surname>Hellman</surname><given-names>J</given-names></name><name><surname>Nakamura</surname><given-names>MC</given-names></name><name><surname>Hsiao</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification</article-title><source>JCI Insight</source><volume>3</volume><elocation-id>e22</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.122958</pub-id><pub-id pub-id-type="pmid">30429363</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barruet</surname><given-names>E</given-names></name><name><surname>Garcia</surname><given-names>SM</given-names></name><name><surname>Striedinger</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Byrnes</surname><given-names>L</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Xuefeng</surname><given-names>S</given-names></name><name><surname>Tamaki</surname><given-names>S</given-names></name><name><surname>Brack</surname><given-names>AS</given-names></name><name><surname>Pomerantz</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Functionally heterogeneous human satellite cells identified by single cell RNA sequencing</article-title><source>eLife</source><volume>9</volume><elocation-id>e51576</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.51576</pub-id><pub-id pub-id-type="pmid">32234209</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becht</surname><given-names>E</given-names></name><name><surname>McInnes</surname><given-names>L</given-names></name><name><surname>Healy</surname><given-names>J</given-names></name><name><surname>Dutertre</surname><given-names>CA</given-names></name><name><surname>Kwok</surname><given-names>IWH</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dimensionality reduction for visualizing single-cell data using UMAP</article-title><source>Nature Biotechnology</source><volume>1</volume><elocation-id>e4314</elocation-id><pub-id pub-id-type="doi">10.1038/nbt.4314</pub-id><pub-id pub-id-type="pmid">30531897</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biferali</surname><given-names>B</given-names></name><name><surname>Proietti</surname><given-names>D</given-names></name><name><surname>Mozzetta</surname><given-names>C</given-names></name><name><surname>Madaro</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fibro-Adipogenic Progenitors Cross-Talk in Skeletal Muscle: The Social Network</article-title><source>Frontiers in Physiology</source><volume>10</volume><elocation-id>1074</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2019.01074</pub-id><pub-id pub-id-type="pmid">31496956</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigot</surname><given-names>A</given-names></name><name><surname>Duddy</surname><given-names>WJ</given-names></name><name><surname>Ouandaogo</surname><given-names>ZG</given-names></name><name><surname>Negroni</surname><given-names>E</given-names></name><name><surname>Mariot</surname><given-names>V</given-names></name><name><surname>Ghimbovschi</surname><given-names>S</given-names></name><name><surname>Harmon</surname><given-names>B</given-names></name><name><surname>Wielgosik</surname><given-names>A</given-names></name><name><surname>Loiseau</surname><given-names>C</given-names></name><name><surname>Devaney</surname><given-names>J</given-names></name><name><surname>Dumonceaux</surname><given-names>J</given-names></name><name><surname>Butler-Browne</surname><given-names>G</given-names></name><name><surname>Mouly</surname><given-names>V</given-names></name><name><surname>Duguez</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Age-Associated Methylation Suppresses SPRY1, Leading to a Failure of Re-quiescence and Loss of the Reserve Stem Cell Pool in Elderly Muscle</article-title><source>Cell Reports</source><volume>13</volume><fpage>1172</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.09.067</pub-id><pub-id pub-id-type="pmid">26526994</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billings</surname><given-names>PC</given-names></name><name><surname>Fiori</surname><given-names>JL</given-names></name><name><surname>Bentwood</surname><given-names>JL</given-names></name><name><surname>O’Connell</surname><given-names>MP</given-names></name><name><surname>Jiao</surname><given-names>X</given-names></name><name><surname>Nussbaum</surname><given-names>B</given-names></name><name><surname>Caron</surname><given-names>RJ</given-names></name><name><surname>Shore</surname><given-names>EM</given-names></name><name><surname>Kaplan</surname><given-names>FS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP)</article-title><source>Journal of Bone and Mineral Research</source><volume>23</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1359/jbmr.071030</pub-id><pub-id pub-id-type="pmid">17967130</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borchin</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Barberi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Derivation and FACS-mediated purification of PAX3+/PAX7+ skeletal muscle precursors from human pluripotent stem cells</article-title><source>Stem Cell Reports</source><volume>1</volume><fpage>620</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2013.10.007</pub-id><pub-id pub-id-type="pmid">24371814</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>TA</given-names></name><name><surname>Lindborg</surname><given-names>CM</given-names></name><name><surname>Bergbauer</surname><given-names>CR</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Kaplan</surname><given-names>FS</given-names></name><name><surname>Pignolo</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP)</article-title><source>Bone</source><volume>109</volume><fpage>259</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2017.08.023</pub-id><pub-id pub-id-type="pmid">28851540</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Orlova</surname><given-names>VV</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Eekhoff</surname><given-names>EMW</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Pan</surname><given-names>G</given-names></name><name><surname>Mummery</surname><given-names>CL</given-names></name><name><surname>Ten Dijke</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva</article-title><source>Stem Cell Reports</source><volume>5</volume><fpage>963</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2015.10.020</pub-id><pub-id pub-id-type="pmid">26626181</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chal</surname><given-names>J</given-names></name><name><surname>Al Tanoury</surname><given-names>Z</given-names></name><name><surname>Hestin</surname><given-names>M</given-names></name><name><surname>Gobert</surname><given-names>B</given-names></name><name><surname>Aivio</surname><given-names>S</given-names></name><name><surname>Hick</surname><given-names>A</given-names></name><name><surname>Cherrier</surname><given-names>T</given-names></name><name><surname>Nesmith</surname><given-names>AP</given-names></name><name><surname>Parker</surname><given-names>KK</given-names></name><name><surname>Pourquié</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro</article-title><source>Nature Protocols</source><volume>11</volume><fpage>1833</fpage><lpage>1850</lpage><pub-id pub-id-type="doi">10.1038/nprot.2016.110</pub-id><pub-id pub-id-type="pmid">27583644</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chal</surname><given-names>J</given-names></name><name><surname>Al Tanoury</surname><given-names>Z</given-names></name><name><surname>Oginuma</surname><given-names>M</given-names></name><name><surname>Moncuquet</surname><given-names>P</given-names></name><name><surname>Gobert</surname><given-names>B</given-names></name><name><surname>Miyanari</surname><given-names>A</given-names></name><name><surname>Tassy</surname><given-names>O</given-names></name><name><surname>Guevara</surname><given-names>G</given-names></name><name><surname>Hubaud</surname><given-names>A</given-names></name><name><surname>Bera</surname><given-names>A</given-names></name><name><surname>Sumara</surname><given-names>O</given-names></name><name><surname>Garnier</surname><given-names>J-M</given-names></name><name><surname>Kennedy</surname><given-names>L</given-names></name><name><surname>Knockaert</surname><given-names>M</given-names></name><name><surname>Gayraud-Morel</surname><given-names>B</given-names></name><name><surname>Tajbakhsh</surname><given-names>S</given-names></name><name><surname>Pourquié</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Recapitulating early development of mouse musculoskeletal precursors of the paraxial mesoderm in vitro</article-title><source>Development</source><volume>145</volume><elocation-id>dev157339</elocation-id><pub-id pub-id-type="doi">10.1242/dev.157339</pub-id><pub-id pub-id-type="pmid">29555813</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>IY</given-names></name><name><surname>Lim</surname><given-names>H</given-names></name><name><surname>Estrellas</surname><given-names>K</given-names></name><name><surname>Mula</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>TV</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Donnelly</surname><given-names>CJ</given-names></name><name><surname>Richard</surname><given-names>J-P</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kazuki</surname><given-names>Y</given-names></name><name><surname>Oshimura</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>HL</given-names></name><name><surname>Hotta</surname><given-names>A</given-names></name><name><surname>Rothstein</surname><given-names>J</given-names></name><name><surname>Maragakis</surname><given-names>N</given-names></name><name><surname>Wagner</surname><given-names>KR</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model</article-title><source>Cell Reports</source><volume>15</volume><fpage>2301</fpage><lpage>2312</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.016</pub-id><pub-id pub-id-type="pmid">27239027</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Convente</surname><given-names>MR</given-names></name><name><surname>Chakkalakal</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>E</given-names></name><name><surname>Caron</surname><given-names>RJ</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Kambayashi</surname><given-names>T</given-names></name><name><surname>Kaplan</surname><given-names>FS</given-names></name><name><surname>Shore</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva</article-title><source>Journal of Bone and Mineral Research</source><volume>33</volume><fpage>269</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3304</pub-id><pub-id pub-id-type="pmid">28986986</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosgrove</surname><given-names>BD</given-names></name><name><surname>Gilbert</surname><given-names>PM</given-names></name><name><surname>Porpiglia</surname><given-names>E</given-names></name><name><surname>Mourkioti</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>SP</given-names></name><name><surname>Corbel</surname><given-names>SY</given-names></name><name><surname>Llewellyn</surname><given-names>ME</given-names></name><name><surname>Delp</surname><given-names>SL</given-names></name><name><surname>Blau</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rejuvenation of the muscle stem cell population restores strength to injured aged muscles</article-title><source>Nature Medicine</source><volume>20</volume><fpage>255</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nm.3464</pub-id><pub-id pub-id-type="pmid">24531378</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culbert</surname><given-names>AL</given-names></name><name><surname>Chakkalakal</surname><given-names>SA</given-names></name><name><surname>Theosmy</surname><given-names>EG</given-names></name><name><surname>Brennan</surname><given-names>TA</given-names></name><name><surname>Kaplan</surname><given-names>FS</given-names></name><name><surname>Shore</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification</article-title><source>Stem Cells</source><volume>32</volume><fpage>1289</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1002/stem.1633</pub-id><pub-id pub-id-type="pmid">24449086</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dey</surname><given-names>D</given-names></name><name><surname>Bagarova</surname><given-names>J</given-names></name><name><surname>Hatsell</surname><given-names>SJ</given-names></name><name><surname>Armstrong</surname><given-names>KA</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Ermann</surname><given-names>J</given-names></name><name><surname>Vonner</surname><given-names>AJ</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Mohedas</surname><given-names>AH</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Eekhoff</surname><given-names>EMW</given-names></name><name><surname>van Schie</surname><given-names>A</given-names></name><name><surname>Demay</surname><given-names>MB</given-names></name><name><surname>Keller</surname><given-names>C</given-names></name><name><surname>Wagers</surname><given-names>AJ</given-names></name><name><surname>Economides</surname><given-names>AN</given-names></name><name><surname>Yu</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification</article-title><source>Science Translational Medicine</source><volume>8</volume><elocation-id>366ra163</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf1090</pub-id><pub-id pub-id-type="pmid">27881824</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsafadi</surname><given-names>M</given-names></name><name><surname>Manikandan</surname><given-names>M</given-names></name><name><surname>Dawud</surname><given-names>RA</given-names></name><name><surname>Alajez</surname><given-names>NM</given-names></name><name><surname>Hamam</surname><given-names>R</given-names></name><name><surname>Alfayez</surname><given-names>M</given-names></name><name><surname>Kassem</surname><given-names>M</given-names></name><name><surname>Aldahmash</surname><given-names>A</given-names></name><name><surname>Mahmood</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transgelin is a TGFβ-inducible gene that regulates osteoblastic and adipogenic differentiation of human skeletal stem cells through actin cytoskeleston organization</article-title><source>Cell Death &amp; Disease</source><volume>7</volume><elocation-id>e2321</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2016.196</pub-id><pub-id pub-id-type="pmid">27490926</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farup</surname><given-names>J</given-names></name><name><surname>Madaro</surname><given-names>L</given-names></name><name><surname>Puri</surname><given-names>PL</given-names></name><name><surname>Mikkelsen</surname><given-names>UR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Interactions between muscle stem cells, mesenchymal-derived cells and immune cells in muscle homeostasis, regeneration and disease</article-title><source>Cell Death &amp; Disease</source><volume>6</volume><elocation-id>e1830</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2015.198</pub-id><pub-id pub-id-type="pmid">26203859</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedrichs</surname><given-names>M</given-names></name><name><surname>Wirsdöerfer</surname><given-names>F</given-names></name><name><surname>Flohé</surname><given-names>SB</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Wuelling</surname><given-names>M</given-names></name><name><surname>Vortkamp</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>BMP signaling balances proliferation and differentiation of muscle satellite cell descendants</article-title><source>BMC Cell Biology</source><volume>12</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2121-12-26</pub-id><pub-id pub-id-type="pmid">21645366</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Furrer</surname><given-names>R</given-names></name><name><surname>Handschin</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><chapter-title>Optimized Engagement of Macrophages and Satellite Cells in the Repair and Regeneration of Exercised Muscle</chapter-title><person-group person-group-type="editor"><name><surname>Spiegelman</surname><given-names>B</given-names></name></person-group><source>Hormones, Metabolism and the Benefits of Exercise</source><publisher-loc>Chamcham</publisher-loc><publisher-name>Furrer R</publisher-name><fpage>57</fpage><lpage>66</lpage></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>S. M</given-names></name><name><surname>Tamaki</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Pomerantz</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Human Satellite Cell Isolation and Xenotransplantation</article-title><source>Methods in Molecular Biology</source><volume>1668</volume><fpage>105</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7283-8_8</pub-id><pub-id pub-id-type="pmid">28842905</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia Steven</surname><given-names>M</given-names></name><name><surname>Tamaki</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Jose</surname><given-names>A</given-names></name><name><surname>Dreux</surname><given-names>J</given-names></name><name><surname>Kouklis</surname><given-names>G</given-names></name><name><surname>Sbitany</surname><given-names>H</given-names></name><name><surname>Seth</surname><given-names>R</given-names></name><name><surname>Knott</surname><given-names>PD</given-names></name><name><surname>Heaton</surname><given-names>C</given-names></name><name><surname>Ryan</surname><given-names>WR</given-names></name><name><surname>Kim</surname><given-names>EA</given-names></name><name><surname>Hansen</surname><given-names>SL</given-names></name><name><surname>Hoffman</surname><given-names>WY</given-names></name><name><surname>Pomerantz</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>High-Yield Purification, Preservation, and Serial Transplantation of Human Satellite Cells</article-title><source>Stem Cell Reports</source><volume>10</volume><fpage>1160</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2018.01.022</pub-id><pub-id pub-id-type="pmid">29478895</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>AJ</given-names></name><name><surname>Rieder</surname><given-names>MK</given-names></name><name><surname>Arnold</surname><given-names>HH</given-names></name><name><surname>Radice</surname><given-names>GL</given-names></name><name><surname>Krauss</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Niche Cadherins Control the Quiescence-to-Activation Transition in Muscle Stem Cells</article-title><source>Cell Reports</source><volume>21</volume><fpage>2236</fpage><lpage>2250</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.10.102</pub-id><pub-id pub-id-type="pmid">29166613</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatsell</surname><given-names>SJ</given-names></name><name><surname>Idone</surname><given-names>V</given-names></name><name><surname>Wolken</surname><given-names>DMA</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Nannuru</surname><given-names>KC</given-names></name><name><surname>Jimenez</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Das</surname><given-names>N</given-names></name><name><surname>Makhoul</surname><given-names>G</given-names></name><name><surname>Chernomorsky</surname><given-names>R</given-names></name><name><surname>D’Ambrosio</surname><given-names>D</given-names></name><name><surname>Corpina</surname><given-names>RA</given-names></name><name><surname>Schoenherr</surname><given-names>CJ</given-names></name><name><surname>Feeley</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>PB</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>Murphy</surname><given-names>AJ</given-names></name><name><surname>Economides</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>303ra137</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aac4358</pub-id><pub-id pub-id-type="pmid">26333933</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haupt</surname><given-names>J</given-names></name><name><surname>Stanley</surname><given-names>A</given-names></name><name><surname>McLeod</surname><given-names>CM</given-names></name><name><surname>Cosgrove</surname><given-names>BD</given-names></name><name><surname>Culbert</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Mourkioti</surname><given-names>F</given-names></name><name><surname>Mauck</surname><given-names>RL</given-names></name><name><surname>Shore</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ACVR1R206H FOP mutation alters mechanosensing and tissue stiffness during heterotopic ossification</article-title><source>Molecular Biology of the Cell</source><volume>30</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1091/mbc.E18-05-0311</pub-id><pub-id pub-id-type="pmid">30379592</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>MR</given-names></name><name><surname>Hiserodt</surname><given-names>J</given-names></name><name><surname>Paras</surname><given-names>K</given-names></name><name><surname>Fujiwara</surname><given-names>W</given-names></name><name><surname>Eskin</surname><given-names>A</given-names></name><name><surname>Jan</surname><given-names>M</given-names></name><name><surname>Xi</surname><given-names>H</given-names></name><name><surname>Young</surname><given-names>CS</given-names></name><name><surname>Evseenko</surname><given-names>D</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name><name><surname>Spencer</surname><given-names>MJ</given-names></name><name><surname>Handel</surname><given-names>BV</given-names></name><name><surname>Pyle</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs</article-title><source>Nature Cell Biology</source><volume>20</volume><fpage>46</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/s41556-017-0010-2</pub-id><pub-id pub-id-type="pmid">29255171</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hino</surname><given-names>K</given-names></name><name><surname>Ikeya</surname><given-names>M</given-names></name><name><surname>Horigome</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Ebise</surname><given-names>H</given-names></name><name><surname>Nishio</surname><given-names>M</given-names></name><name><surname>Sekiguchi</surname><given-names>K</given-names></name><name><surname>Shibata</surname><given-names>M</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name><name><surname>Matsuda</surname><given-names>S</given-names></name><name><surname>Toguchida</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neofunction of ACVR1 in fibrodysplasia ossificans progressiva</article-title><source>PNAS</source><volume>112</volume><fpage>15438</fpage><lpage>15443</lpage><pub-id pub-id-type="doi">10.1073/pnas.1510540112</pub-id><pub-id pub-id-type="pmid">26621707</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>AB</given-names></name><name><surname>Brack</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Muscle Stem Cells and Aging</article-title><source>Current Topics in Developmental Biology</source><volume>126</volume><fpage>299</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/bs.ctdb.2017.08.008</pub-id><pub-id pub-id-type="pmid">29305003</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuang</surname><given-names>S</given-names></name><name><surname>Kuroda</surname><given-names>K</given-names></name><name><surname>Le Grand</surname><given-names>F</given-names></name><name><surname>Rudnicki</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Asymmetric self-renewal and commitment of satellite stem cells in muscle</article-title><source>Cell</source><volume>129</volume><fpage>999</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.03.044</pub-id><pub-id pub-id-type="pmid">17540178</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lees-Shepard</surname><given-names>JB</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Biswas</surname><given-names>AA</given-names></name><name><surname>Stoessel</surname><given-names>SJ</given-names></name><name><surname>Nicholas</surname><given-names>SAE</given-names></name><name><surname>Cogswell</surname><given-names>CA</given-names></name><name><surname>Devarakonda</surname><given-names>PM</given-names></name><name><surname>Schneider</surname><given-names>MJ</given-names></name><name><surname>Cummins</surname><given-names>SM</given-names></name><name><surname>Legendre</surname><given-names>NP</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Kaartinen</surname><given-names>V</given-names></name><name><surname>Hunter</surname><given-names>JW</given-names></name><name><surname>Goldhamer</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Activin-dependent signaling in fibro/adipogenic progenitors causes fibrodysplasia ossificans progressiva</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>471</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-02872-2</pub-id><pub-id pub-id-type="pmid">29396429</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukjanenko</surname><given-names>L</given-names></name><name><surname>Karaz</surname><given-names>S</given-names></name><name><surname>Stuelsatz</surname><given-names>P</given-names></name><name><surname>Gurriaran-Rodriguez</surname><given-names>U</given-names></name><name><surname>Michaud</surname><given-names>J</given-names></name><name><surname>Dammone</surname><given-names>G</given-names></name><name><surname>Sizzano</surname><given-names>F</given-names></name><name><surname>Mashinchian</surname><given-names>O</given-names></name><name><surname>Ancel</surname><given-names>S</given-names></name><name><surname>Migliavacca</surname><given-names>E</given-names></name><name><surname>Liot</surname><given-names>S</given-names></name><name><surname>Jacot</surname><given-names>G</given-names></name><name><surname>Metairon</surname><given-names>S</given-names></name><name><surname>Raymond</surname><given-names>F</given-names></name><name><surname>Descombes</surname><given-names>P</given-names></name><name><surname>Palini</surname><given-names>A</given-names></name><name><surname>Chazaud</surname><given-names>B</given-names></name><name><surname>Rudnicki</surname><given-names>MA</given-names></name><name><surname>Bentzinger</surname><given-names>CF</given-names></name><name><surname>Feige</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Aging Disrupts Muscle Stem Cell Function by Impairing Matricellular WISP1 Secretion from Fibro-Adipogenic Progenitors</article-title><source>Cell Stem Cell</source><volume>24</volume><fpage>433</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.12.014</pub-id><pub-id pub-id-type="pmid">30686765</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magli</surname><given-names>A</given-names></name><name><surname>Incitti</surname><given-names>T</given-names></name><name><surname>Kiley</surname><given-names>J</given-names></name><name><surname>Swanson</surname><given-names>SA</given-names></name><name><surname>Darabi</surname><given-names>R</given-names></name><name><surname>Rinaldi</surname><given-names>F</given-names></name><name><surname>Selvaraj</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>A</given-names></name><name><surname>Tolar</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Thomson</surname><given-names>JA</given-names></name><name><surname>Perlingeiro</surname><given-names>RCR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PAX7 Targets, CD54, Integrin α9β1, and SDC2, Allow Isolation of Human ESC/iPSC-Derived Myogenic Progenitors</article-title><source>Cell Reports</source><volume>19</volume><fpage>2867</fpage><lpage>2877</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.06.005</pub-id><pub-id pub-id-type="pmid">28658631</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Schlieve</surname><given-names>CR</given-names></name><name><surname>Ikeya</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Sami</surname><given-names>S</given-names></name><name><surname>Baba</surname><given-names>S</given-names></name><name><surname>Barruet</surname><given-names>E</given-names></name><name><surname>Nasu</surname><given-names>A</given-names></name><name><surname>Asaka</surname><given-names>I</given-names></name><name><surname>Otsuka</surname><given-names>T</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name><name><surname>Conklin</surname><given-names>BR</given-names></name><name><surname>Toguchida</surname><given-names>J</given-names></name><name><surname>Hsiao</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation</article-title><source>Orphanet Journal of Rare Diseases</source><volume>8</volume><elocation-id>190</elocation-id><pub-id pub-id-type="doi">10.1186/1750-1172-8-190</pub-id><pub-id pub-id-type="pmid">24321451</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>K</given-names></name><name><surname>Chavez</surname><given-names>RD</given-names></name><name><surname>Barruet</surname><given-names>E</given-names></name><name><surname>Hsiao</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification</article-title><source>Current Osteoporosis Reports</source><volume>17</volume><fpage>387</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1007/s11914-019-00541-x</pub-id><pub-id pub-id-type="pmid">31721068</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>Koji</given-names></name><name><surname>Lepinski</surname><given-names>A</given-names></name><name><surname>Chavez</surname><given-names>RD</given-names></name><name><surname>Barruet</surname><given-names>E</given-names></name><name><surname>Pereira</surname><given-names>A</given-names></name><name><surname>Moody</surname><given-names>TA</given-names></name><name><surname>Ton</surname><given-names>AN</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Hellman</surname><given-names>J</given-names></name><name><surname>Tomoda</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>MC</given-names></name><name><surname>Hsiao</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ACVR1R206H extends inflammatory responses in human induced pluripotent stem cell-derived macrophages</article-title><source>Bone</source><volume>153</volume><elocation-id>e116129</elocation-id><pub-id pub-id-type="doi">10.1016/j.bone.2021.116129</pub-id><pub-id pub-id-type="pmid">34311122</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauro</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1961">1961</year><article-title>Satellite cell of skeletal muscle fibers</article-title><source>The Journal of Biophysical and Biochemical Cytology</source><volume>9</volume><fpage>493</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1083/jcb.9.2.493</pub-id><pub-id pub-id-type="pmid">13768451</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>AP</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain</article-title><source>Cell</source><volume>62</volume><fpage>1073</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90385-r</pub-id><pub-id pub-id-type="pmid">2205396</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medici</surname><given-names>D</given-names></name><name><surname>Shore</surname><given-names>EM</given-names></name><name><surname>Lounev</surname><given-names>VY</given-names></name><name><surname>Kaplan</surname><given-names>FS</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name><name><surname>Olsen</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Conversion of vascular endothelial cells into multipotent stem-like cells</article-title><source>Nature Medicine</source><volume>16</volume><fpage>1400</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1038/nm.2252</pub-id><pub-id pub-id-type="pmid">21102460</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>C</given-names></name><name><surname>Lisiecki</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>S</given-names></name><name><surname>Levin</surname><given-names>A</given-names></name><name><surname>Fayad</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Sono</surname><given-names>T</given-names></name><name><surname>McCarthy</surname><given-names>E</given-names></name><name><surname>Levi</surname><given-names>B</given-names></name><name><surname>James</surname><given-names>AW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Heterotopic Ossification: A Comprehensive Review</article-title><source>JBMR Plus</source><volume>3</volume><elocation-id>e10172</elocation-id><pub-id pub-id-type="doi">10.1002/jbm4.10172</pub-id><pub-id pub-id-type="pmid">31044187</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nastase</surname><given-names>MV</given-names></name><name><surname>Young</surname><given-names>MF</given-names></name><name><surname>Schaefer</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Biglycan: a multivalent proteoglycan providing structure and signals</article-title><source>The Journal of Histochemistry and Cytochemistry</source><volume>60</volume><fpage>963</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1369/0022155412456380</pub-id><pub-id pub-id-type="pmid">22821552</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikitovic</surname><given-names>D</given-names></name><name><surname>Papoutsidakis</surname><given-names>A</given-names></name><name><surname>Karamanos</surname><given-names>NK</given-names></name><name><surname>Tzanakakis</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response</article-title><source>Matrix Biology</source><volume>35</volume><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2013.09.003</pub-id><pub-id pub-id-type="pmid">24060754</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Calhabeu</surname><given-names>F</given-names></name><name><surname>Morgan</surname><given-names>JE</given-names></name><name><surname>Katagiri</surname><given-names>T</given-names></name><name><surname>Amthor</surname><given-names>H</given-names></name><name><surname>Zammit</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>BMP signalling permits population expansion by preventing premature myogenic differentiation in muscle satellite cells</article-title><source>Cell Death and Differentiation</source><volume>18</volume><fpage>222</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1038/cdd.2010.95</pub-id><pub-id pub-id-type="pmid">20689554</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Teichmann</surname><given-names>SA</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Bodenmiller</surname><given-names>B</given-names></name><name><surname>Campbell</surname><given-names>P</given-names></name><name><surname>Carninci</surname><given-names>P</given-names></name><name><surname>Clatworthy</surname><given-names>M</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Deplancke</surname><given-names>B</given-names></name><name><surname>Dunham</surname><given-names>I</given-names></name><name><surname>Eberwine</surname><given-names>J</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Enard</surname><given-names>W</given-names></name><name><surname>Farmer</surname><given-names>A</given-names></name><name><surname>Fugger</surname><given-names>L</given-names></name><name><surname>Göttgens</surname><given-names>B</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Haniffa</surname><given-names>M</given-names></name><name><surname>Hemberg</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Kriegstein</surname><given-names>A</given-names></name><name><surname>Lein</surname><given-names>E</given-names></name><name><surname>Linnarsson</surname><given-names>S</given-names></name><name><surname>Lundberg</surname><given-names>E</given-names></name><name><surname>Lundeberg</surname><given-names>J</given-names></name><name><surname>Majumder</surname><given-names>P</given-names></name><name><surname>Marioni</surname><given-names>JC</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Mhlanga</surname><given-names>M</given-names></name><name><surname>Nawijn</surname><given-names>M</given-names></name><name><surname>Netea</surname><given-names>M</given-names></name><name><surname>Nolan</surname><given-names>G</given-names></name><name><surname>Pe’er</surname><given-names>D</given-names></name><name><surname>Phillipakis</surname><given-names>A</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Quake</surname><given-names>S</given-names></name><name><surname>Reik</surname><given-names>W</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Sanes</surname><given-names>J</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Shalek</surname><given-names>A</given-names></name><name><surname>Shapiro</surname><given-names>E</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Shin</surname><given-names>JW</given-names></name><name><surname>Stegle</surname><given-names>O</given-names></name><name><surname>Stratton</surname><given-names>M</given-names></name><name><surname>Stubbington</surname><given-names>MJT</given-names></name><name><surname>Theis</surname><given-names>FJ</given-names></name><name><surname>Uhlen</surname><given-names>M</given-names></name><name><surname>van Oudenaarden</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Watt</surname><given-names>F</given-names></name><name><surname>Weissman</surname><given-names>J</given-names></name><name><surname>Wold</surname><given-names>B</given-names></name><name><surname>Xavier</surname><given-names>R</given-names></name><name><surname>Yosef</surname><given-names>N</given-names></name><collab>Human Cell Atlas Meeting Participants</collab></person-group><year iso-8601-date="2017">2017</year><article-title>The Human Cell Atlas</article-title><source>eLife</source><volume>6</volume><elocation-id>e27041</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.27041</pub-id><pub-id pub-id-type="pmid">29206104</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satija</surname><given-names>R</given-names></name><name><surname>Farrell</surname><given-names>JA</given-names></name><name><surname>Gennert</surname><given-names>D</given-names></name><name><surname>Schier</surname><given-names>AF</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Spatial reconstruction of single-cell gene expression data</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>495</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/nbt.3192</pub-id><pub-id pub-id-type="pmid">25867923</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepers</surname><given-names>K</given-names></name><name><surname>Hsiao</surname><given-names>EC</given-names></name><name><surname>Garg</surname><given-names>T</given-names></name><name><surname>Scott</surname><given-names>MJ</given-names></name><name><surname>Passegué</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice</article-title><source>Blood</source><volume>120</volume><fpage>3425</fpage><lpage>3435</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-11-395418</pub-id><pub-id pub-id-type="pmid">22859604</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seale</surname><given-names>P</given-names></name><name><surname>Sabourin</surname><given-names>LA</given-names></name><name><surname>Girgis-Gabardo</surname><given-names>A</given-names></name><name><surname>Mansouri</surname><given-names>A</given-names></name><name><surname>Gruss</surname><given-names>P</given-names></name><name><surname>Rudnicki</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Pax7 is required for the specification of myogenic satellite cells</article-title><source>Cell</source><volume>102</volume><fpage>777</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)00066-0</pub-id><pub-id pub-id-type="pmid">11030621</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segalés</surname><given-names>J</given-names></name><name><surname>Perdiguero</surname><given-names>E</given-names></name><name><surname>Muñoz-Cánoves</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Regulation of Muscle Stem Cell Functions: A Focus on the p38 MAPK Signaling Pathway</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>4</volume><elocation-id>e91</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2016.00091</pub-id><pub-id pub-id-type="pmid">27626031</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shea</surname><given-names>KL</given-names></name><name><surname>Xiang</surname><given-names>W</given-names></name><name><surname>LaPorta</surname><given-names>VS</given-names></name><name><surname>Licht</surname><given-names>JD</given-names></name><name><surname>Keller</surname><given-names>C</given-names></name><name><surname>Basson</surname><given-names>MA</given-names></name><name><surname>Brack</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration</article-title><source>Cell Stem Cell</source><volume>6</volume><fpage>117</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2009.12.015</pub-id><pub-id pub-id-type="pmid">20144785</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>M</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Carpenedo</surname><given-names>RL</given-names></name><name><surname>Demers</surname><given-names>SP</given-names></name><name><surname>Stanford</surname><given-names>WL</given-names></name><name><surname>Skerjanc</surname><given-names>IS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Derivation and expansion of PAX7-positive muscle progenitors from human and mouse embryonic stem cells</article-title><source>Stem Cell Reports</source><volume>3</volume><fpage>516</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2014.07.001</pub-id><pub-id pub-id-type="pmid">25241748</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>de Gorter</surname><given-names>DJJ</given-names></name><name><surname>Hoogaars</surname><given-names>WMH</given-names></name><name><surname>’t Hoen</surname><given-names>PAC</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Overactive bone morphogenetic protein signaling in heterotopic ossification and Duchenne muscular dystrophy</article-title><source>Cellular and Molecular Life Sciences</source><volume>70</volume><fpage>407</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1007/s00018-012-1054-x</pub-id><pub-id pub-id-type="pmid">22752156</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shore</surname><given-names>E. M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, or--how does one tissue become another?</article-title><source>Wiley Interdisciplinary Reviews. Developmental Biology</source><volume>1</volume><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1002/wdev.9</pub-id><pub-id pub-id-type="pmid">22408652</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shore Eileen</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Feldman</surname><given-names>GJ</given-names></name><name><surname>Fenstermacher</surname><given-names>DA</given-names></name><name><surname>Cho</surname><given-names>T-J</given-names></name><name><surname>Choi</surname><given-names>IH</given-names></name><name><surname>Connor</surname><given-names>JM</given-names></name><name><surname>Delai</surname><given-names>P</given-names></name><name><surname>Glaser</surname><given-names>DL</given-names></name><name><surname>LeMerrer</surname><given-names>M</given-names></name><name><surname>Morhart</surname><given-names>R</given-names></name><name><surname>Rogers</surname><given-names>JG</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Triffitt</surname><given-names>JT</given-names></name><name><surname>Urtizberea</surname><given-names>JA</given-names></name><name><surname>Zasloff</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Kaplan</surname><given-names>FS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva</article-title><source>Nature Genetics</source><volume>38</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/ng1783</pub-id><pub-id pub-id-type="pmid">16642017</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shultz</surname><given-names>LD</given-names></name><name><surname>Lyons</surname><given-names>BL</given-names></name><name><surname>Burzenski</surname><given-names>LM</given-names></name><name><surname>Gott</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chaleff</surname><given-names>S</given-names></name><name><surname>Kotb</surname><given-names>M</given-names></name><name><surname>Gillies</surname><given-names>SD</given-names></name><name><surname>King</surname><given-names>M</given-names></name><name><surname>Mangada</surname><given-names>J</given-names></name><name><surname>Greiner</surname><given-names>DL</given-names></name><name><surname>Handgretinger</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells</article-title><source>Journal of Immunology</source><volume>174</volume><fpage>6477</fpage><lpage>6489</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.10.6477</pub-id><pub-id pub-id-type="pmid">15879151</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soriano-Arroquia</surname><given-names>A</given-names></name><name><surname>McCormick</surname><given-names>R</given-names></name><name><surname>Molloy</surname><given-names>AP</given-names></name><name><surname>McArdle</surname><given-names>A</given-names></name><name><surname>Goljanek-Whysall</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Age-related changes in miR-143-3p:Igfbp5 interactions affect muscle regeneration</article-title><source>Aging Cell</source><volume>15</volume><fpage>361</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1111/acel.12442</pub-id><pub-id pub-id-type="pmid">26762731</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>CI</given-names></name><name><surname>Baba</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Hua</surname><given-names>EA</given-names></name><name><surname>Sears</surname><given-names>MAF</given-names></name><name><surname>Fu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Balijepalli</surname><given-names>S</given-names></name><name><surname>Tomoda</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Lizarraga</surname><given-names>P</given-names></name><name><surname>Wojciak</surname><given-names>J</given-names></name><name><surname>Scheinman</surname><given-names>MM</given-names></name><name><surname>Aalto-Setälä</surname><given-names>K</given-names></name><name><surname>Makielski</surname><given-names>JC</given-names></name><name><surname>January</surname><given-names>CT</given-names></name><name><surname>Healy</surname><given-names>KE</given-names></name><name><surname>Kamp</surname><given-names>TJ</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name><name><surname>Conklin</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia</article-title><source>Stem Cell Reports</source><volume>3</volume><fpage>269</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2014.06.003</pub-id><pub-id pub-id-type="pmid">25254341</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>A</given-names></name><name><surname>Heo</surname><given-names>SJ</given-names></name><name><surname>Mauck</surname><given-names>RL</given-names></name><name><surname>Mourkioti</surname><given-names>F</given-names></name><name><surname>Shore</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis</article-title><source>Journal of Bone and Mineral Research</source><volume>34</volume><fpage>1894</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3760</pub-id><pub-id pub-id-type="pmid">31107558</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stantzou</surname><given-names>A</given-names></name><name><surname>Schirwis</surname><given-names>E</given-names></name><name><surname>Swist</surname><given-names>S</given-names></name><name><surname>Alonso-Martin</surname><given-names>S</given-names></name><name><surname>Polydorou</surname><given-names>I</given-names></name><name><surname>Zarrouki</surname><given-names>F</given-names></name><name><surname>Mouisel</surname><given-names>E</given-names></name><name><surname>Beley</surname><given-names>C</given-names></name><name><surname>Julien</surname><given-names>A</given-names></name><name><surname>Le Grand</surname><given-names>F</given-names></name><name><surname>Garcia</surname><given-names>L</given-names></name><name><surname>Colnot</surname><given-names>C</given-names></name><name><surname>Birchmeier</surname><given-names>C</given-names></name><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>Schuelke</surname><given-names>M</given-names></name><name><surname>Relaix</surname><given-names>F</given-names></name><name><surname>Amthor</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>BMP signaling regulates satellite cell-dependent postnatal muscle growth</article-title><source>Development</source><volume>144</volume><fpage>2737</fpage><lpage>2747</lpage><pub-id pub-id-type="doi">10.1242/dev.144089</pub-id><pub-id pub-id-type="pmid">28694257</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Hafemeister</surname><given-names>C</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Mauck</surname><given-names>WM</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive Integration of Single-Cell Data</article-title><source>Cell</source><volume>177</volume><fpage>1888</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id><pub-id pub-id-type="pmid">31178118</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>MP</given-names></name><name><surname>Torres</surname><given-names>SJ</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Heterotopic ossification after central nervous system trauma: A current review</article-title><source>Bone &amp; Joint Research</source><volume>2</volume><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1302/2046-3758.23.2000152</pub-id><pub-id pub-id-type="pmid">23610702</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Ohnuki</surname><given-names>M</given-names></name><name><surname>Narita</surname><given-names>M</given-names></name><name><surname>Ichisaka</surname><given-names>T</given-names></name><name><surname>Tomoda</surname><given-names>K</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title><source>Cell</source><volume>131</volume><fpage>861</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.11.019</pub-id><pub-id pub-id-type="pmid">18035408</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Team</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2014">2014</year><data-title>A language and environment for statistical computing</data-title><version designator="2.6.2">2.6.2</version><source>R:Development Core Team</source></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Cacchiarelli</surname><given-names>D</given-names></name><name><surname>Grimsby</surname><given-names>J</given-names></name><name><surname>Pokharel</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Morse</surname><given-names>M</given-names></name><name><surname>Lennon</surname><given-names>NJ</given-names></name><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Mikkelsen</surname><given-names>TS</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/nbt.2859</pub-id><pub-id pub-id-type="pmid">24658644</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urist</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="1965">1965</year><article-title>Bone: formation by autoinduction</article-title><source>Science</source><volume>150</volume><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1126/science.150.3698.893</pub-id><pub-id pub-id-type="pmid">5319761</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Wal</surname><given-names>E</given-names></name><name><surname>Herrero-Hernandez</surname><given-names>P</given-names></name><name><surname>Wan</surname><given-names>R</given-names></name><name><surname>Broeders</surname><given-names>M</given-names></name><name><surname>In ’t Groen</surname><given-names>SLM</given-names></name><name><surname>van Gestel</surname><given-names>TJM</given-names></name><name><surname>van IJcken</surname><given-names>WFJ</given-names></name><name><surname>Cheung</surname><given-names>TH</given-names></name><name><surname>van der Ploeg</surname><given-names>AT</given-names></name><name><surname>Schaaf</surname><given-names>GJ</given-names></name><name><surname>Pijnappel</surname><given-names>WWMP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Large-Scale Expansion of Human iPSC-Derived Skeletal Muscle Cells for Disease Modeling and Cell-Based Therapeutic Strategies</article-title><source>Stem Cell Reports</source><volume>10</volume><fpage>1975</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2018.04.002</pub-id><pub-id pub-id-type="pmid">29731431</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volpato</surname><given-names>V</given-names></name><name><surname>Webber</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility</article-title><source>Disease Models &amp; Mechanisms</source><volume>13</volume><elocation-id>dmm042317</elocation-id><pub-id pub-id-type="doi">10.1242/dmm.042317</pub-id><pub-id pub-id-type="pmid">31953356</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wosczyna</surname><given-names>MN</given-names></name><name><surname>Rando</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Muscle Stem Cell Support Group: Coordinated Cellular Responses in Muscle Regeneration</article-title><source>Developmental Cell</source><volume>46</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2018.06.018</pub-id><pub-id pub-id-type="pmid">30016618</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Matthias</surname><given-names>N</given-names></name><name><surname>Lo</surname><given-names>J</given-names></name><name><surname>Ortiz-Vitali</surname><given-names>JL</given-names></name><name><surname>Shieh</surname><given-names>AW</given-names></name><name><surname>Wang</surname><given-names>SH</given-names></name><name><surname>Darabi</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Myogenic Double-Reporter Human Pluripotent Stem Cell Line Allows Prospective Isolation of Skeletal Muscle Progenitors</article-title><source>Cell Reports</source><volume>25</volume><fpage>1966</fpage><lpage>1981</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.10.067</pub-id><pub-id pub-id-type="pmid">30428361</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>H</given-names></name><name><surname>Fujiwara</surname><given-names>W</given-names></name><name><surname>Gonzalez</surname><given-names>K</given-names></name><name><surname>Jan</surname><given-names>M</given-names></name><name><surname>Liebscher</surname><given-names>S</given-names></name><name><surname>Van Handel</surname><given-names>B</given-names></name><name><surname>Schenke-Layland</surname><given-names>K</given-names></name><name><surname>Pyle</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>In Vivo Human Somitogenesis Guides Somite Development from hPSCs</article-title><source>Cell Reports</source><volume>18</volume><fpage>1573</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.01.040</pub-id><pub-id pub-id-type="pmid">28178531</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>H</given-names></name><name><surname>Langerman</surname><given-names>J</given-names></name><name><surname>Sabri</surname><given-names>S</given-names></name><name><surname>Chien</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>CS</given-names></name><name><surname>Younesi</surname><given-names>S</given-names></name><name><surname>Hicks</surname><given-names>M</given-names></name><name><surname>Gonzalez</surname><given-names>K</given-names></name><name><surname>Fujiwara</surname><given-names>W</given-names></name><name><surname>Marzi</surname><given-names>J</given-names></name><name><surname>Liebscher</surname><given-names>S</given-names></name><name><surname>Spencer</surname><given-names>M</given-names></name><name><surname>Van Handel</surname><given-names>B</given-names></name><name><surname>Evseenko</surname><given-names>D</given-names></name><name><surname>Schenke-Layland</surname><given-names>K</given-names></name><name><surname>Plath</surname><given-names>K</given-names></name><name><surname>Pyle</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Human Skeletal Muscle Atlas Identifies the Trajectories of Stem and Progenitor Cells across Development and from Human Pluripotent Stem Cells</article-title><source>Cell Stem Cell</source><volume>27</volume><fpage>158</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.04.017</pub-id><pub-id pub-id-type="pmid">32396864</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wilschut</surname><given-names>KJ</given-names></name><name><surname>Kouklis</surname><given-names>G</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Hesse</surname><given-names>R</given-names></name><name><surname>Garland</surname><given-names>C</given-names></name><name><surname>Sbitany</surname><given-names>H</given-names></name><name><surname>Hansen</surname><given-names>S</given-names></name><name><surname>Seth</surname><given-names>R</given-names></name><name><surname>Knott</surname><given-names>PD</given-names></name><name><surname>Hoffman</surname><given-names>WY</given-names></name><name><surname>Pomerantz</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Human Satellite Cell Transplantation and Regeneration from Diverse Skeletal Muscles</article-title><source>Stem Cell Reports</source><volume>5</volume><fpage>419</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2015.07.016</pub-id><pub-id pub-id-type="pmid">26352798</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>GXY</given-names></name><name><surname>Terry</surname><given-names>JM</given-names></name><name><surname>Belgrader</surname><given-names>P</given-names></name><name><surname>Ryvkin</surname><given-names>P</given-names></name><name><surname>Bent</surname><given-names>ZW</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Ziraldo</surname><given-names>SB</given-names></name><name><surname>Wheeler</surname><given-names>TD</given-names></name><name><surname>McDermott</surname><given-names>GP</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Gregory</surname><given-names>MT</given-names></name><name><surname>Shuga</surname><given-names>J</given-names></name><name><surname>Montesclaros</surname><given-names>L</given-names></name><name><surname>Underwood</surname><given-names>JG</given-names></name><name><surname>Masquelier</surname><given-names>DA</given-names></name><name><surname>Nishimura</surname><given-names>SY</given-names></name><name><surname>Schnall-Levin</surname><given-names>M</given-names></name><name><surname>Wyatt</surname><given-names>PW</given-names></name><name><surname>Hindson</surname><given-names>CM</given-names></name><name><surname>Bharadwaj</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Ness</surname><given-names>KD</given-names></name><name><surname>Beppu</surname><given-names>LW</given-names></name><name><surname>Deeg</surname><given-names>HJ</given-names></name><name><surname>McFarland</surname><given-names>C</given-names></name><name><surname>Loeb</surname><given-names>KR</given-names></name><name><surname>Valente</surname><given-names>WJ</given-names></name><name><surname>Ericson</surname><given-names>NG</given-names></name><name><surname>Stevens</surname><given-names>EA</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Mikkelsen</surname><given-names>TS</given-names></name><name><surname>Hindson</surname><given-names>BJ</given-names></name><name><surname>Bielas</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Massively parallel digital transcriptional profiling of single cells</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14049</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14049</pub-id><pub-id pub-id-type="pmid">28091601</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66107.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ackert-Bicknell</surname><given-names>Cheryl</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Colorado</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The manuscript by Barruet et al., investigates an interesting and rare skeletal muscle dystrophy (FOP). They use both primary and induced (iPSC) muscle stem cells to determine how regeneration/engraftment is affected in this condition. The authors use a blend of histology and transcriptional approaches to determine ECM remodeling and myogenic capacity from both cell/tissue lines. The experiments are well conducted and use strong approaches and statistical measures to test their hypothesis. Overall, this is a quality manuscript on a rare muscle disease that will establish a novel model to study FOP and initial data to elucidate the molecular pathology of HO.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66107.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ackert-Bicknell</surname><given-names>Cheryl</given-names></name><role>Reviewing Editor</role><aff><institution>University of Colorado</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;<italic>ACVR1</italic><sup><italic>R206H</italic></sup> increases osteogenic/ECM gene expression and impairs myofiber formation in human skeletal muscle stem cells&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Kathryn Cheah as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. A major concern for this study is that there is a small sample size herein and it was felt that the statistical analysis was lacking. It is understood that FOP is a rare genetic disease and obtaining a patient sample is extremely difficult. However, all of the data in Figure 1 is obtained from two patients. Conclusions drawn from an n=2 need to be appropriately circumspect.</p><p>2. In the transplantation experiments, several samples had zero engraftments while other samples had extremely low engraftment even in the control group less than 0.1% of cells were engrafted. If you exclude non-engrafted recipients, all of the results are inconclusive. This issue was raised by all of the reviewers.</p><p>3. Some of the representative images do not really show what the authors are claiming. I am not sure whether this is due to low-resolution images or not but it is difficult to see whether these are really expressing myogenic proteins or if they are false positives. Moreover, in Figure 2E, there are more samples that do not express PAX7 and MYOGENIN than cells that do. Without reaching statistical significance, authors cannot claim their conclusion that hiPSC have differentiated into MuSC like cells. Furthermore, authors should have tested other myogenic genes such as MYOD, MYF5, MRF. DYSTROPHIN was not a choice of protein for immunofluorescence.</p><p>4. Compared to fibrosis and lipid infiltration, heterotopic ossification in muscle is a rare incidence that only occurs following traumatic injury or limb amputations. Even FOP is a rare genetic disorder. Thus, authors should not generalize that HO is a common abnormality that follows a lack of muscle repair or regeneration.</p><p>5. There are several reports that suggest fibrogenic/adipogenic progenitors aberrantly differentiate into HO phenotype. The authors fail to discuss the importance of FAPs in adult myogenesis and muscle stem cell niche as potential confounding factors altering BMP signaling in FOP or HO.</p><p>6. The introduction must be re-written to clarify the rationale and objectives of the study. It should be re-focused around the mechanisms of FOP and synthesize previous data on FOP and the cell types involved. There is confusion between heterotopic ossification and FOP as these conditions may cause ectopic bone formation in skeletal muscle through independent mechanisms. The rationale for manipulating BMP signaling for generating hiMPCs is also unclear and maybe not justified.</p><p>7. The title is misleading and should be edited to include establishing a model, not highlighting the functional consequences of the gene mutation, which I believe are clinically implied.</p><p>8. Figure 2 should include quantitative data and higher quality images. One limitation is the lack of isogenic control for the FOP lines. This limitation should be mentioned in the discussion.</p><p>9. Figure 3 should include FMO control or non-labelled cells. In panel B, statistical analyses should be performed on data from biological replicates only and not biological + technical replicates.</p><p>10. Figure 6: What are the identities of non-myogenic clusters?</p><p>11. If the authors want to imply function, are there inhibitors to this pathway that could serve to reverse the pathology in this model? I see BMP inhibitors are used however, targeting upstream (i.e. effecting the activin receptor itself) mechanisms would serve as a more direct proof of concept experiment.</p><p>12. It would be interesting if the BMP or activin inhibitor would affect transplantation efficiency. From what I can tell, the LDN inhibitor was only used in vitro.</p><p>13. Results show low efficiency of myogenic differentiation from hiMPCs and variable engraftment capacity that is not affected by ACVR1R206H mutation.</p><p>14. The authors conclude that the abnormal expression of ECM and chondro/osteogenic markers by FOP iMPC may modulate the niche environment and may favor ectopic ossification. This conclusion thus requires stronger results to support it.</p><p>For the scRNAseq analyses presented in Figures 4 and 5:</p><p>15. Overall, the reviewers found this section interesting, but there were many flaws/concerns raised with the analysis conducted. Some interpretations of scRNAseq are not fully supported by the results. The cells of interest (skeletal muscle stem cells) appear very diluted in the dataset. The expression of ECM and chondro/osteogenic markers by FOP iMPCs is not convincing and more specific chondro/osteogenic markers should be analyzed.</p><p>16. Fewer cells were analysed in the control sample compared to FOP sample. The authors should indicate whether analyses were performed to compensate for differences in the sequencing depth.</p><p>17. In Figure 4, very few Pax7+ and Myod + cells are detected in the myogenic cluster. To what extent are the differences between control and FOP samples due to non pax7+ cells?</p><p>18. The non-myogenic clusters should be better characterized in Figure 4. The myogenic clusters should also be better defined in Figure 5, especially clusters 0 and 2.</p><p>19. In Figure 5, cluster # should be specified in panel B.</p><p>20. The pseudotime analyses are were very confusing to the reviewers and the suitability and rigor of this analysis was questioned. The starting point A contains cluster 4 cells that are MYOG+ and MYOD1+. In panel D, how can differentiation markers exhibit a non-linear progression? Chondro/osteogenic markers should be validated and more specific.</p><p><italic>Reviewer #1:</italic></p><p>The study by Barruet et al., reports interesting observations on muscle stem/satellite cells derived from fibrodysplasia ossificans progressiva (FOP) patients, both hiPSC differentiated into SC-like cells and primary cells. The authors performed a variety of transplantation/histological analyses, as well as transcriptional profiling. Weaknesses were noted with the data analysis and in places, claims on mechanism were overly strongly stated.</p><p><italic>Reviewer #2:</italic></p><p>Barruet et al., explore the impact of ACVR1R206H mutation responsible for FOP on skeletal muscle stem cells. In this rare genetic disease, over-activating point mutation in ACVR1 causes ectopic bone formation within skeletal muscles. This pathological response may occur due in part to abnormal skeletal muscle repair following injury, yet the cellular bases are not fully understood. Previous studies have revealed that the cells of origin for the ectopic bone formation are mesenchymal populations within the skeletal muscle interstitium, the fibro-adipo-progenitors (FAP), while ACVR1R206H mutation in other cell types such as endothelial cells or muscle stem cells alone do not cause the disease. However, the ACVR1R206H mutation in cell types other than FAP may contribute to the abnormal tissue environment and to the progression of the disease. Research aiming to elucidate the cellular mechanisms of FOP is hampered by the difficulty to have access to patient samples as muscle biopsy itself can trigger an injury response contributing to disease progression. Dr. Hsiao's team has developed over the past years the iPSCs technology to obtain FOP iPSCs in order to assess the consequences of ACVR1R206H mutation in several cell lineages. In this study, the authors concentrate on the myogenic lineage, and compare the muscle regenerative potential and transcriptome profiling by scRNAseq of iPSC-derived muscle stem/progenitor cells (iMPCs) and primary human muscle stem cells (Hu-MuSCs). Overall the data is of high quality. The results reveal that Hu-MuSCs from FOP patients have reduced regenerative potential compared to control. Reduced engraftment capacity was observed for Hu-MuSCs isolated from biceps but not diaphragm muscle. This correlates with the fact that diaphragm muscle is less affected in FOP, although results from diaphragm control would have further supported the claim. The authors used iPSCs from FOP patients and control to perform scRNAseq analyses. Reporting the similarities and differences in transcriptional signature of primary Hu-MuSCs and hiMPCs is an important contribution to the field and validates the use of iMPCs to further elucidate disease mechanisms. The conclusions drawn from the data presented were overreaching, which was in part due to a lack of clarity in the stated problem statement they were trying to address.</p><p><italic>Reviewer #3:</italic></p><p>The manuscript by Barruet et al., investigates an interesting and rare skeletal muscle dystrophy (FOP). They use both primary and induced (iPSC) muscle stem cells to determine how regeneration/engraftment is affected in this condition. The authors use a blend of histology and transcriptional approaches to determine EMC remodeling and myogenic capacity from both cell/tissue lines. The experiments are well conducted and use strong approaches and statistical measures to test their hypothesis. Overall, this is a quality manuscript on a rare muscle disease that will establish a novel model to study FOP and initial data to elucidate the molecular pathology of HO.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66107.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. A major concern for this study is that there is a small sample size herein and it was felt that the statistical analysis was lacking. It is understood that FOP is a rare genetic disease and obtaining a patient sample is extremely difficult. However, all of the data in Figure 1 is obtained from two patients. Conclusions drawn from an n=2 need to be appropriately circumspect.</p></disp-quote><p>We agree that the small sample size is a major limitation of our study, specifically in Figure 1. However, the ability to collect more samples is hampered by the rarity of FOP, and even more infrequent donations of autopsy material suitable for our studies particularly in the setting of COVID19. We clarify this limitation throughout our manuscript (including within the limitations section of our discussion), and note this limitation in the conclusion for Figure 1 accordingly.</p><disp-quote content-type="editor-comment"><p>2. In the transplantation experiments, several samples had zero engraftments while other samples had extremely low engraftment even in the control group less than 0.1% of cells were engrafted. If you exclude non-engrafted recipients, all of the results are inconclusive. This issue was raised by all of the reviewers.</p></disp-quote><p>In our study, the engraftment efficiency of the sorted human primary control satellite cell is comparable to previously published reports (Xu et al., 2015 Stem Cell Reports; Garcia et al., 2018 Stem Cell Reports). We agree that the low engraftment of our iMPCs poses challenges for our analysis. We explore several reasons for this, including the possibility of other cell types present in the cultures (as described in Figure 4B-C) such as neuroprogenitor, neuroepithelial, glial, and mesenchymal cells. In addition, we believe that inclusion of the low engraftment efficiency samples in our data analyses is important, since we did not know if the ACVR1 mutation might increase engraftment. Such an unexpected effect was previously observed, where the <italic>ACVR1 <sup>R206H</sup></italic> mutation unexpectedly increased efficiency of iPSC formation (Hayashi, et al., PNAS, 2016). We revised the discussion to better state this limitation, and adjusted text throughout the manuscript to clarify this limitation.</p><disp-quote content-type="editor-comment"><p>3. Some of the representative images do not really show what the authors are claiming. I am not sure whether this is due to low-resolution images or not but it is difficult to see whether these are really expressing myogenic proteins or if they are false positives. Moreover, in Figure 2E, there are more samples that do not express PAX7 and MYOGENIN than cells that do. Without reaching statistical significance, authors cannot claim their conclusion that hiPSC have differentiated into MuSC like cells. Furthermore, authors should have tested other myogenic genes such as MYOD, MYF5, MRF. DYSTROPHIN was not a choice of protein for immunofluorescence.</p></disp-quote><p>Thank you for identifying these concerns. We included new images with higher resolution that better show the expression of myogenic proteins in Figure 2. We now include images showing MYOGENIN staining in addition to PAX7 and DYSTROPHIN (Figure 2B,C). In Figure 2D, the heterogeneity of our myogenic gene expression data can be explained by the presence of other cells types which has been described previously (Shelton et al., 2015 Stem Cell Reports; Hicks et al., 2018 Nat Cell Biol) and shown in Figure 2—figure supplement 1B with TUJ-1 staining, Figure 3, and Figure 3—figure supplement 1A with FACS analysis for CD45 (hematopoietic cells) and CD31 (endothelial cells). We believe our new images better show our conclusion that hiPSCs have differentiated into hMuSC-like cells. We also added the gene expression analysis by qPCR of <italic>MYOD1</italic> and <italic>MYF5</italic> to support our findings.</p><disp-quote content-type="editor-comment"><p>4. Compared to fibrosis and lipid infiltration, heterotopic ossification in muscle is a rare incidence that only occurs following traumatic injury or limb amputations. Even FOP is a rare genetic disorder. Thus, authors should not generalize that HO is a common abnormality that follows a lack of muscle repair or regeneration.</p></disp-quote><p>We agree that fibrosis and lipid infiltration are important signs of muscle damage. However, heterotopic ossification is a surprisingly common event. In addition to traumatic injury or limb amputations, heterotopic ossification also affects patients with burns, CNS injury, rheumatologic disorders, and surgery (Matsuo et al., 2019 Curr Osteoporos Rep; Agarwal et al., 2016 PNAS; Meyers et al., 2019 JBMR Plus; Sullivan et al., 2013 Bone Joint Res), and more recently as a rare but significant COVID-19 complication (Aziz et al., 2021 Radiol Case Rep).</p><p>We revised the introduction and discussion to include this information for better context, and also made minor changes throughout the manuscript to indicate that HO is an uncommon but significant complication of muscle injury.</p><disp-quote content-type="editor-comment"><p>5. There are several reports that suggest fibrogenic/adipogenic progenitors aberrantly differentiate into HO phenotype. The authors fail to discuss the importance of FAPs in adult myogenesis and muscle stem cell niche as potential confounding factors altering BMP signaling in FOP or HO.</p></disp-quote><p>We expanded our discussion of FAPs in the introduction and discussion, and how their cross-talk with satellite cells may impact the pathogenesis of FOP or HO in general.</p><disp-quote content-type="editor-comment"><p>6. The introduction must be re-written to clarify the rationale and objectives of the study. It should be re-focused around the mechanisms of FOP and synthesize previous data on FOP and the cell types involved. There is confusion between heterotopic ossification and FOP as these conditions may cause ectopic bone formation in skeletal muscle through independent mechanisms. The rationale for manipulating BMP signaling for generating hiMPCs is also unclear and maybe not justified.</p></disp-quote><p>The introduction has been reorganized to help clarify the rationale and objectives. We also clarified our rational for examining how manipulating BMP signaling impacts generating Hu-MuSC like cells.</p><disp-quote content-type="editor-comment"><p>7. The title is misleading and should be edited to include establishing a model, not highlighting the functional consequences of the gene mutation, which I believe are clinically implied.</p></disp-quote><p>We have accepted the modified title. Thank you for this suggestion. “Modeling the <italic>ACVR1</italic><sup><italic>R206H</italic></sup> mutation in human skeletal muscle stem cells”</p><disp-quote content-type="editor-comment"><p>8. Figure 2 should include quantitative data and higher quality images. One limitation is the lack of isogenic control for the FOP lines. This limitation should be mentioned in the discussion.</p></disp-quote><p>Higher quality images have been added to Figure 2. Since immunohistochemistry is a semi-quantitative assay and significantly impacted by the staining efficiency and specificity of the antibodies, we believe the relative expression assessments found in Figure 2D, which are based on real time qPCR, provide a more accurate quantitative assessment.</p><p>The lack of isogenic lines and its consequent limitation are included in the discussion and the limitations section.</p><disp-quote content-type="editor-comment"><p>9. Figure 3 should include FMO control or non-labelled cells. In panel B, statistical analyses should be performed on data from biological replicates only and not biological + technical replicates.</p></disp-quote><p>Non-labeled cells are now included in the Figure 3—figure supplement 1C. Statistical analyses are now performed on biological replicates and are represented in Panel B of Figure 3.</p><p>In panel B, statistical analyses have been performed on 6 biological replicates using a two-way ANOVA Tukey test where the mean of each cell line was used. All 6 cell lines, with their own technical replicates, are shown in Figure 3B. We also performed statistical analyses on Ctrl vs FOP for each sort groups and found no significance.</p><disp-quote content-type="editor-comment"><p>10. Figure 6: What are the identities of non-myogenic clusters?</p></disp-quote><p>The identities of non-myogenic clusters are now clearly labelled in Figures 6B and C.</p><disp-quote content-type="editor-comment"><p>11. If the authors want to imply function, are there inhibitors to this pathway that could serve to reverse the pathology in this model? I see BMP inhibitors are used however, targeting upstream (i.e. effecting the activin receptor itself) mechanisms would serve as a more direct proof of concept experiment.</p></disp-quote><p>Thank you for suggesting those experiments in which we could better tease out the mechanism by using upstream inhibitors such as activin A neutralizing antibodies. As discussed in our manuscript, the number of primary muscle stem cells we can obtain from FOP patients is extremely limited, and so we are unable to test such inhibitors in vivo using these primary cells. In addition, strategies to directly target <italic>ACVR1</italic><sup><italic>WT</italic></sup> vs. <italic>ACVR1</italic><sup><italic>R206H</italic></sup> receptors are still being developed. Also, the direct targeting of the BMP pathway b the inhibitors will also inhibit the aberrant signaling induced by Activin A on ACVR1<sup>R206H</sup>. We hope to examine these intriguing questions in the future, using our human iPSC models and novel pathway inhibitors. This is clarified in the limitations paragraph of the discussion.</p><disp-quote content-type="editor-comment"><p>12. It would be interesting if the BMP or activin inhibitor would affect transplantation efficiency. From what I can tell, the LDN inhibitor was only used in vitro.</p></disp-quote><p>We agree that this would be a very interesting question to pursue. LDN has a long track record of being used to inhibit the SMAD signaling pathways of the BMPs, and particularly the signaling downstream of ACVR1, and in our results suggested benefits for both FOP and control cells in myogenic differentiation. However, the heterogeneity in our current studies, the relatively low efficiency of transplantation by both control and FOP cells, and the lack of large numbers of primary cells prevent us from dissecting further the other signaling circuitry of ACVR1 (ie SMAD vs. p38, or ACVR1 itself). We hope to pursue these detailed studies in the future. This is clarified in the limitations paragraph of the discussion.</p><disp-quote content-type="editor-comment"><p>13. Results show low efficiency of myogenic differentiation from hiMPCs and variable engraftment capacity that is not affected by ACVR1R206H mutation.</p></disp-quote><p>This is a current limitation of our system, and affects both control and <italic>ACVR1</italic><sup><italic>R206H</italic></sup> cells. We include a more detailed discussion of the low engraftment efficiency in our discussion.</p><disp-quote content-type="editor-comment"><p>14. The authors conclude that the abnormal expression of ECM and chondro/osteogenic markers by FOP iMPC may modulate the niche environment and may favor ectopic ossification. This conclusion thus requires stronger results to support it.</p></disp-quote><p>We have revised our Results section 7 to include additional explanation of our rationale, and also added additional information in the discussion.</p><p>For the scRNAseq analyses presented in Figures 4 and 5:</p><disp-quote content-type="editor-comment"><p>15. Overall, the reviewers found this section interesting, but there were many flaws/concerns raised with the analysis conducted. Some interpretations of scRNAseq are not fully supported by the results. The cells of interest (skeletal muscle stem cells) appear very diluted in the dataset. The expression of ECM and chondro/osteogenic markers by FOP iMPCs is not convincing and more specific chondro/osteogenic markers should be analyzed.</p></disp-quote><p>We edited the section on scRNAseq results to better clarify our results and conclusions. Although at first glance it may seem that the muscle stem cells are too diluted in the dataset, we note that despite the overall number of cells per sample (7309 cells after filtering), the proportion of the population of interest (1009 cells or 13.8%) is still higher than physiological proportion (2-7%, Yablonka-Reuveni et al., 2011 J Histochem Cytochem). While higher cell numbers are often preferable, our studies using 1000 muscle cells is in fact a reasonable number: Past studies on rare population have been performed on similar or lower cell number (Rubenstein et al., 2020 Scientific reports; De Micheli et al., 2020 Cell Reports). In addition, using the Seurat algorithm (https://satijalab.org/howmanycells/) we would need only 624 cells to be 95% confident that our sample contains at least 5 cells from each cell types. Thus, we believe our analyses are reflective of the underlying biology we are observing.</p><p>We analyzed the expression of typical chondro/osteogenic markers that have been found to be altered in other cell types carrying the <italic>ACVR1</italic><sup><italic>R206H</italic></sup> mutation. This is now presented in Figure 5—figure supplement 1F,G. <italic>SP7</italic> (Osterix) was not found to be expressed. Overall, those markers have very low level of expression, relatively few cells expressed them and none of them were significantly differentially expressed. <italic>Sox9</italic> expression is increased in FOP clusters.</p><p>We also analyzed the expression of cinq genes (<italic>CYR61</italic>, <italic>CTGF</italic>, <italic>NOV</italic> and <italic>WISPs</italic>) which have been shown to be induced during the process of trauma-induced HO and where WISP1 may have act as a negative regulator (Hsu et al., 2020 JCI Insight). None of those genes were significantly differentially expresse; however, CTGF expression was increased in FOP cells. Because this does not significantly impact our conclusions, these data are provided for the reviewer but not included in the current version of the manuscript.</p><disp-quote content-type="editor-comment"><p>16. Fewer cells were analysed in the control sample compared to FOP sample. The authors should indicate whether analyses were performed to compensate for differences in the sequencing depth.</p></disp-quote><p>As noted by the reviewer, the reads per cell value differs between the control and FOP samples. However, as indicated in Figure 4-Source Data1, the Median Genes per cells is equivalent, thus compensating for the reads/cell difference and making our comparison relevant. Hence, we did not perform compensatory analyses, but have chosen to represent our results using Violin plots. These plots enable visualization of the probability density of a given gene expression in various samples, thus minimizing cell number bias between samples.</p><disp-quote content-type="editor-comment"><p>17. In Figure 4, very few Pax7+ and Myod + cells are detected in the myogenic cluster. To what extent are the differences between control and FOP samples due to non pax7+ cells?</p></disp-quote><p>We thank the reviewer for raising this important question. One major limitation of scRNAseq is the low sensitivity that doesn’t detect all transcripts; therefore, scRNAseq analyses use unsupervised clustering as an unbiased way to identify various cell populations and subtypes. At the time this study was performed, the 3’ v2 kit from 10X Genomics was standard, and thus was used for this study. Additional published studies from our groups and others on human satellite cells have shown that this newer version can detect higher proportion of PAX7 expressing satellite cells (Barruet et al., 2020 <italic>eLife</italic>; Dell’Orso et al., 2019 Development). Despite the low amount of non-PAX7+ cells we were still able to confirm findings from our FOP primary Hu-MuSCs showing an increase in ECM and chondro-osteogenic markers.</p><disp-quote content-type="editor-comment"><p>18. The non-myogenic clusters should be better characterized in Figure 4. The myogenic clusters should also be better defined in Figure 5, especially clusters 0 and 2.</p></disp-quote><p>Thank you for this suggestion. The non-myogenic clusters have been characterized and properly labelled in Figure 4 and Figure 5.</p><disp-quote content-type="editor-comment"><p>19. In Figure 5, cluster # should be specified in panel B.</p></disp-quote><p>Cluster numbers are now specified in 5A (see reviewer’s comment #18).</p><disp-quote content-type="editor-comment"><p>20. The pseudotime analyses are were very confusing to the reviewers and the suitability and rigor of this analysis was questioned. The starting point A contains cluster 4 cells that are MYOG+ and MYOD1+. In panel D, how can differentiation markers exhibit a non-linear progression? Chondro/osteogenic markers should be validated and more specific.</p></disp-quote><p>We re-performed the pseudotime analyses in Figure 5 D-F as suggested, and adjusted the branch order for the pseudotime trajectories of myogenic markers for more clarity. While pseudotime analysis does not always reflect linear time, it can be useful to map gene expression changes that occur between cell populations. HuMuSC differentiation and return to quiescence is a dynamic process. Indeed, under the right stimuli, HuMuSCs undergo asymmetric division after proliferation by either self-renewal to replenish their pool or differentiation to form myotubes (Feige et al., 2018 Cell Stem Cell). It is highly probable that similar changes are happening in our myogenic differentiation thus exhibiting a non-linear progression of the myogenic markers. Indeed, our scRNAseq analysis shows different states of muscle stem cells in Figure 5B. The tip of branch A is now constituted of cycling muscle stem cells that have low expression of <italic>MYOG</italic>. The drop of <italic>MYOD1</italic> expression can be associated with cells returning to a more quiescent state such as cluster 0 which is located along to more proximal end of branch A and in the branches’ intersection (Figure 5F). As expected, the myoblast cluster has higher level of <italic>MYOG</italic> and <italic>MYOD1</italic> expression.</p><p>Chrondro/osteogenic markers that have been reported to be upregulated in FOP cells are analyzed and shown in Figure 5—figure supplement1 (see reviewer’s comment #15).</p></body></sub-article></article>